GEDEON RICHTER PLC.

Half-yearly report to the Budapest Stock Exchange
for the period ended 30 June 2024

Table of Contents

I. Management Report
for the period ended 30 June 2024

1. Executive Summary

"I am very pleased with our strong double-digit growth in 2024 in three of our four segments with General Medicines also catching up impressively during Q2. Profitability improved across the business and we remain well on track to meet our full-year ambitions and targets.

We have made major progress lately in our key Women's Healthcare franchise. Acquiring Estetrol and a specialized R&D capability will allow us to sustain growth, solidify our leadership and continue to provide innovative solutions to women in areas of significant unmet needs.

EMA's acceptance of our denosumab file reflects an important milestone in building the biosimilar portfolio. Half-way through the year we have already achieved a lot thanks to our dedicated and talented teams across the globe, and we are not done yet for 2024… stay with us! "

Gábor Orbán

Selected consolidated business metrics	HUFm			EURm	
	2024	**2023**	**Change**	**2024**	**2023**
	6 months to June		%	6 months to June	
Revenues	419,693	413,436	1.5	1,076.1	1,085.1
Gross profit	291,971	256,307	13.9	748.6	672.7
Gross margin (%)	69.6	62.0			
EBIT	**126,485**	**95,013**	**33.1**	**324.3**	**249.4**
EBIT margin (%)	30.1	23.0			
Clean EBIT*	135,961	111,183	22.3	348.6	291.8
Clean EBIT margin (%)	32.4	26.9			
Net profit**	138,215	67,936	103.4	354.4	178.3
Free cash-flow	111,353	41,536	168.1	285.5	109.0
EPS (HUF, EUR)	756	365	107.1	1.94	0.96
ROE (%)	19.6	11.7			
Cash conversion cycle (days)	329.6	209.9	57.0		

Notes:

* Clean EBIT (cEBIT) = Gross profit less Operating Expenses (S&M, G&A, R&D) less Claw-back expenses plus milestone income.

** Net profit: Profit attributable to the owners of the parent

2. Group turnover

Consolidated turnover in the first half of 2024 at HUF 419,693m increased by 1.5% when compared with turnover achieved in the base period, as a result of Pharma sales exceeding figures reported in the first six months to June 2023 by 14.1%, which was largely offset by declining Wholesale and retail figures subsequent to the divestiture of the Romanian W&R business in May 2023. Nearly 99% of consolidated turnover originated in the Pharmaceutical segment in the first half of 2024. In the the following sections the report offers further details to the latter.

3. Turnover of Pharmaceuticals

Sales by Geographies	HUFm			EURm	
	2024	2023	Change	2024	2023
	6 months to June		%	6 months to June	
EUROPE	**247,080**	**226,645**	**9.0**	**633.5**	**594.9**
WEU	76,109	65,269	16.6	195.2	171.3
CEU	86,407	76,353	13.2	221.5	200.4
EEU	84,564	85,023	-0.5	216.8	223.2
NORTHAM	**116,457**	**97,845**	**19.0**	**298.6**	**256.8**
LATAM	**15,732**	11,876	32.5	40.3	31.2
APAC	**29,520**	21,265	38.8	75.7	55.8
ROW	**4,589**	4,508	1.8	11.8	11.8
Total	**413,379**	**362,139**	**14.1**	**1,059.9**	**950.5**

Top 10 Markets	HUFm			EURm	
	2024	2023	Change	2024	2023
	6 months to June		%	6 months to June	
USA	114,143	95,939	19.0	292.7	251.8
Russia	58,852	63,033	-6.6	150.9	165.4
Hungary	28,974	26,299	10.2	74.3	69.0
Poland	22,900	18,823	21.7	58.7	49.4
China	18,458	12,913	42.9	47.3	33.9
Germany	18,120	13,855	30.8	46.5	36.4
Spain	13,318	12,083	10.2	34.1	31.7
Romania	10,184	8,139	25.1	26.1	21.4
Italy	9,342	7,778	20.1	24.0	20.4
United Kingdom	8,824	6,491	35.9	22.6	17.0
Top10 Markets Total	**303,115**	**265,353**	**14.2**	**777.2**	**696.4**
Total turnover	**413,379**	**362,139**	**14.1**	**1,059.9**	**950.5**
Total Top 10 / Total turnover %				**73.3**	**73.3**

Top10 products	HUFm			EURm	
	2024	2023	Change	2024	2023
	6 months to June		%	6 months to June	
Vraylar® / Reagila® / cariprazine	110,093	89,844	22.5	282.3	235.8
Oral Contraceptives	80,337	72,805	10.3	206.0	191.1
Evra®	17,609	14,704	19.8	45.2	38.6
Mydeton / Mydocalm	13,102	13,564	-3.4	33.6	35.6
Terrosa® / teriparatide	13,050	10,292	26.8	33.5	27.0
Cavinton	10,970	9,597	14.3	28.1	25.2
Verospiron	9,828	9,414	4.4	25.2	24.7
Bemfola®	9,449	12,357	-23.5	24.2	32.4
Aflamin	8,864	6,562	35.1	22.7	17.2
Panangin	8,363	9,967	-16.1	21.4	26.2
Top10 products Total	**281.665**	**249,106**	**13.1**	**722.2**	**653.8**
Total turnover	**413,379**	**362,139**	**14.1**	**1,059.9**	**950.5**
Total Top 10 / Total turnover %				**68.1**	**68.8**

4. Performance of Business Units

4.1. Presentation of the Business Units

Richter's Management defined new strategic guidelines for the Company in 2010. While reaffirming the previously outlined strategic direction, new action plans have been determined in 2018 and consequently, six strategic pillars have been identified. These strategic pillars were reorganised into four Business Units, and new heads appointed with complete P&L responsibility. In addition to the above four strategic pillars, additional activities classified as belonging to the Pharmaceutical segment were included into a fifth, non-focus pillar. The reporting structure was also realigned to reflect these changes. The business units are as follows:

Neuropsychiatry (CNS)

Women's Healthcare (WHC)

Biotechnology (BIO)

General Medicines (GM)

A detailed presentation of each of the above business units can be found in Condensed Consolidated Financial Statements on pages 34-36.

Turnover of these four Business Units is presented in detail in the following.

4.2. Neuropsyichiatry (CNS)

	HUFm			EURm	
	2024	**2023**	**Change**	**2024**	**2023**
	6 months to June		%	6 months to June	
Cariprazine	109,418	89,410	22.4	280.6	234.7
Vraylar® royalty (USA)	102,019	83,963	21.5	261.6	220.4
Vraylar® royalty (CA)	179	77	133.8	0.5	0.2
Vraylar® royalty (PR)	57	25	128.8	0.1	0.1
Reagila®	7,162	5,346	34.0	18.4	14.0

Cariprazine, our flagship product discovered by Richter scientists in the early 2000s was launched in 2016 in the USA under the trademark, Vraylar®. The product is marketed in Western Europe by Recordati while Richter performs sales and marketing activities for this product in Central Europe and Eastern Europe under the brand name Reagila®. Richter has signed a number of bilateral agreements to commercialize Reagila® in other non-European markets.

About 94% of the product turnover originates in North America and is denominated in USD. Vraylar® royalty income due to Richter in the first half of 2024 amounted to HUF 102,255m (USD 277.5m). The figures above also include royalty income paid on AbbVie sales recorded in Canada. HUF denominated turnover was positively impacted by favourable exchange rate movements experienced in the reported period.

Proceeds from Reagila® amounted to HUF 7,162m (EUR 18.4m) during the reported period.

Global Reach

Altogether by the end of the first half of 2024 cariprazine was available in 65 countries globally including the USA and Hungary, with reimbursement status in most countries.

Notes on CNS profitability

AbbVie's sales performance of Vraylar® continued to grow by double digit compared to the base period.

An increase of clean EBIT was partly restrained by considerably higher R&D expenses. In addition to the above, improving sales performance of Reagila® also contributed positively to higher profitability recorded by this business unit.

4.3. Women's Healthcare (WHC)

Sales by Products	HUFm			EURm	
	2024	2023	Change	2024	2023
	6 months to June		%	6 months to June	
WHC	149,519	129,738	15.2	383.4	340.5
OCs	78,675	71,263	10.4	201.7	187.0
of which Drovelis®	7,762	5,240	48.1	19.9	13.8
Evra®	17,609	14,704	19.8	45.2	38.6
Bemfola®	9,449	12,357	-23.5	24.2	32.4
Cyclogest®	3,602	2,912	23.7	9.2	7.6
Ryeqo®	7,090	2,403	195.1	18.2	6.3
Lenzetto®	5,083	3,327	52.8	13.0	8.7

Sales by Geographies	HUFm			EURm	
	2024	2023	Change	2024	2023
	6 months to June		%	6 months to June	
EUROPE	**104,792**	**96,605**	**8.5**	**268.6**	**253.6**
WEU	**53,201**	**46,742**	**13.8**	**136.4**	**122.7**
Spain	9,701	8,775	10.5	24.9	23.0
Germany	9,317	8,034	16.0	23.9	21.1
Italy	7,411	6,231	18.9	19.0	16.4
UK	7,127	5,461	30.5	18.3	14.3
France	5,580	5,694	-2.0	14.3	14.9
CEU	**21,545**	**18,635**	**15.6**	**55.2**	**48.9**
Poland	7,929	6,581	20.5	20.3	17.3
EEU	**30,046**	**31,228**	**-3.8**	**77.0**	**82.0**
Russia	25,000	26,267	-4.8	64.1	68.9
NORTHAM	**8,018**	**7,328**	**9.4**	**20.6**	**19.2**
USA	6,397	5,817	10.0	16.4	15.3
LATAM	**13,834**	**9,908**	**39.6**	**35.5**	**26.0**
Mexico	5,525	3,476	59.0	14.2	9.1
APAC	**19,953**	**12,770**	**56.2**	**51.2**	**33.5**
China	17,526	10,521	66.6	44.9	27.6
ROW	**2,922**	**3,127**	**-6.6**	**7.5**	**8.2**
Total	**149,519**	**129,738**	**15.2**	**383.4**	**340.5**

Sales of the WHC product group increased primarily due to the higher turnover of oral contraceptives together with direct sales income received from Ryeqo®, Evra® and Lenzetto®.

Sales of Ryeqo® recorded excellent growth also due to its launch in endometriosis indication primarily in Western Europe, most notably in Germany, Spain and Italy. Drovelis®, launched in 2021, also contributed materially to sales growth achieved during the reported year. Sales of Drovelis® grew primarily in Western Europe notably in Italy, Germany, Portugal and Spain. The product also showed strong performance during the reported year in Poland. In addition, sales of Drovelis® in Russia also increased on the back of certain price increases among other factors.

Portfolio management

Most important products / product groups belonging to this business unit and launched during the reported period in one or more new markets within the respective regions, were as follows:

Product / Product group	EUROPE WEU	EUROPE CEU	EUROPE EEU	NORTHAM	LATAM	APAC	ROW
OCs	X				X		
Drovelis®		X	X		X		
Evra®			X		X		X
Ryeqo®			X				
Lenzetto®			X		X	X	
GISKIT	X	X				X	
Other WHC products	X	X			X		

Turnover of key WHC products by geographies

Bemfola®

	HUFm			EURm	
	2024	2023	Change	2024	2023
	6 months to June		%	6 months to June	
EUROPE	**8,861**	**11,614**	**-23.7**	**22.7**	**30.5**
WEU	7,440	9,879	-24.7	19.0	25.9
CEU	1,354	1,717	-21.1	3.5	4.5
EEU	67	18	272.2	0.2	0.1
LATAM	**346**	**251**	**37.8**	**0.9**	**0.6**
APAC	**242**	**492**	**-50.8**	**0.6**	**1.3**
Total	**9,449**	**12,357**	**-23.5**	**24.2**	**32.4**

Higher sales of Bemfola® achieved primarily in Ukraine and certain Latin American countries were more than offset by lower turnover experienced in Greece, Spain, France, other Western European countries, in Poland and in South Korea. Sales of this product to Poland also fell behind performance recorded in the first half of 2023. These declines were consequences of some supply chain challenges experienced in certain territories.

Evra®

	HUFm			EURm	
	2024	2023	Change	2024	2023
	6 months to June		%	6 months to June	
EUROPE	**7,966**	**6,680**	**19.3**	**20.4**	**17.5**
WEU	5,427	4,860	11.7	13.9	12.8
CEU	1,784	1,532	16.4	4.6	4.0
EEU	755	288	162.2	1.9	0.7
NORTHAM	**1,622**	**1,467**	**10.6**	**4.2**	**3.9**
LATAM	**6,616**	**4,832**	**36.9**	**17.0**	**12.7**
APAC	**0**	**36**	**-100.0**	**0.0**	**0.1**
ROW	**1,405**	**1,689**	**-16.8**	**3.6**	**4.4**
Total	**17,609**	**14,704**	**19.8**	**45.2**	**38.6**

The agreements concluded in 2021 with Janssen Pharmaceutica NV provided for post-closing transitional support to facilitate the transfer of the Outside US marketing authorizations. In the reported period Evra® ranked 3rd on our Top10 products list. A significant increase in the turnover of this product reported in Latin America was driven primarily by higher sales levels achieved in Mexico. In addition turnover also grew in some Western European countries, notably in Netherlands and the UK.

Acquisitions announced during the reported period

On 11 June 2024 Richter announced that it acquired 100% of the shares in Estetra SRL and Neuralis SA, as well as some assets and licences of Mithra R&D. The transaction was closed upon signature (see Note 17 on page 54-57).

On 19 June 2024 Richter announced that it has acquired BCI Pharma, a Belgium-based privately-owned biotech company, carrying out innovative research activity in a variety of Women's Health conditions. BCI identifies novel kinase inhibitors from its proprietary library of kinase inhibitors (small chemical molecules) derived from HTS (High-Throughput Screening) (see Note 17 on page 54-57).

Notes on WHC profitability

A double digit growth in revenue characterised our WHC portfolio across the most important markets of Europe, APAC (China) and LATAM. Higher turnover achieved in the latter two regions was also supported by certain preshipments.

The increase of gross profit reported reflects primarily a volume growth combined with positive changes in the sales mix with expanding sales volumes of high margin oral contraceptives and innovative products.

Additional positive impacts were experienced at clean EBIT level including a contained increase of sales and marketing expenses together with a significant drop in R&D expenses, partly resulting from an exceptionally high base and from a different timing of these expenses in the reported period.

4.4. Biotechnology (BIO)

Turnover of teriparatide

Total sales proceeds from teriparatide amounted to HUF 13,049m (EUR 33.5m) in the first half of 2024. Sales proceeds from Japan contributed HUF 3,964m representing 18% of total sales achieved by the product. Subsequent to the completion at the end of May of the acquisitions announced in early March sales figures for teriparatide include one month worth of total proceeds from Richter-Helm BioTec GmbH & Co. KG .

	HUFm			EURm	
	2024	**2023**	**Change**	**2024**	**2023**
	6 months to June		%	6 months to June	
EUROPE	**10,099**	**8,156**	**23.8**	**25.9**	**21.4**
WEU	8,967	7,317	22.5	23.0	19.2
CEE	1,133	839	35.0	2.9	2.2
LATAM	**201**	**103**	**95.3**	**0.5**	**0.3**
APAC	**2,634**	**1,994**	**32.1**	**6.8**	**5.2**
OTHER	**114**	**35**	**222.9**	**0.3**	**0.1**
Total	**13,049**	**10,289**	**26.8**	**33.5**	**27.0**

Turnover of CDMO projects

Sales of the Biotechnology Business Unit includes HUF 13,472m (EUR 34.5m) of CDMO projects in addition to turnover of teriparatide. These figures increased by 22.3% in HUF terms (by 19.4% in EUR terms) when compared to the first half of 2023.

Acquisitions announced during the reported period

On 29 January 2024 Richter announced that subsequent to previously established trustful collaboration with Germany based Formycon AG, it became a strategic investor in Formycon via cash capital increase in the amount of 9.08% of Formycon's share capital. The transaction enables the parties to jointly leverage strategic long-term opportunities throughout the entire biosimilar value chain including development, manufacturing, and commercial phases.

On 6 March 2024 Richter announced that it acquired 50% stake in Richter-Helm BioTec GmbH & Co. KG and 30% stake in Richter-Helm BioLogics GmbH & Co. KG. to become 100% owner of both companies. The transaction was closed on 31 May 2024 (see Note 17 on page 54-57).

R&D activities carried out in Biotechnology

On 18 July 2024 Richter announced that the European Medicines Agency (EMA) has accepted Richter's two marketing authorization applications (MAAs) for its proposed biosimilar to denosumab.

Notes on BIO profitability

Gross profit of this business unit slightly declined. Volatility of this segment is highly impacted by the performance of CDMO projects the accounting of which differs significantly from that of product sales. One month worth of royalty proceeds of Richter-Helm Biotec GmbH & Co. KG also contributed to the improving performance.

Clean EBIT margin improved significantly when compared to the first six months to June 2023 period primarily due to higher milestone income recorded in the reported period.

Significantly higher overall turnover of CDMO projects also contributed to higher sales levels in this business unit in the reported period. Biosimilar product development activities and measures aiming to improve efficiency commenced in the previous quarters were continued.

4.5. General Medicines (GM)

Sales by geographies	HUFm			EURm	
	2024	2023	Change	2024	2023
	6 months to June		%	6 months to June	
EUROPE	**114,862**	**107,655**	**6.7**	**294.5**	**282.6**
CEU	**59,973**	**52,900**	**13.4**	**153.8**	**138.8**
Hungary	24,445	22,415	9.1	62.7	58.8
Poland	13,978	11,553	21.0	35.8	30.3
Romania	7,911	6,235	26.9	20.3	16.4
EEU	**53,288**	**52,882**	**0.8**	**136.6**	**138.8**
Russia	33,049	35,957	-8.1	84.7	94.4
Kazakhstan	3,486	3,440	1.3	8.9	9.0
Ukraine	3,722	3,239	14.9	9.5	8.5
Uzbekistan	5,399	3,042	77.5	13.8	8.0
All other regions*	**8,159**	**8,778**	**-7.1**	**20.9**	**23.1**
Total	**121,420**	**114,560**	**6.0**	**311.3**	**300.7**

* Note: All other regions include WEU, LATAM, APAC and ROW regions.

Hungary

The underlying market increased by 9.3% in value terms during the five months to May 2024 period, while retail sales growth of Richter products were 9.0% higher when compared to the first five months of 2023 according to the latest available IQVIA data. The Company ranks first amongst players in the Hungarian generic pharmaceutical market with a market share of 14.9%. Taking into account the prescription drugs retail market alone, Richter qualifies for second place with a market share of 7.3%.

Poland

Turnover in Poland increased by 21.0% in HUF terms, or 10.4% in PLN terms in the six months to June 2024 and totalled HUF 13,978m (PLN 154.7m). The sales of anti inflammatory Aflamin, anticoagulant Dabigatran and diuretic Verospiron and ACE blocker Lisopress contributed the most to higher turnover realised on this market. Certain preshipments realised at the end of the second quarter positively impacted the performance achieved.

Romania

General Medicines sales in Romania were HUF 7,911m (RON 100.9m) in the first half of 2024. Sales increased by 26.9% (24.9% in RON terms) primarily driven by certain price increases implemented in the second half of 2023.

Russia

Sales to Russia at HUF 33,049m (RUB 8,388.1m) declined by 8.1% in HUF terms (increased by 7.8% in RUB terms). The exchange rate of RUB against the HUF declined on average by 14.7% compared to first half of 2023. Notwithstanding a volatile market environment presenting unforeseeable risks connected to the ongoing war and the subsequent sanctions imposed on Russia, business operations prevailed broadly at levels experienced prior to the war. Sales in this business unit were primarily driven by rheumatology and cardiovascular products.

Price increases impacted our year-on-year performance achieved during the reported period on this market by an average of 7.2% implemented on our portfolio of non-EDL drugs. Slightly declining volumes at the wholesaler level were therefore more than offset by the higher prices applied.

In-market sales figures (IQVIA, data for the first five months of 2024) suggest that retail sales recorded in RUB terms by Richter products increased by 10.7% falling behind overall market growth at 14.1% in RUB terms. Richter's market share on the generic market is 4.2%.

Ukraine

Sales reported in Ukraine in the first half of 2024, at HUF 3,722m (EUR 9.5m) increased by 14.9% (12.3% in EUR terms) compared to the same period of 2023.

Due to a change in Ukrainian legislation, marketing authorizations issued for products having sufficient competitors on the market may be revoked if their manufacturer operates manufacturing units and pays taxes in Russia. A procedure implementing the suspension of 53 of our products was initiated in October 2022 on this legal basis. Authorities warned the Company that should it maintain its Russian manufacturing base, marketing authorizations will be revoked in respect of 10 Richter brands sold in 29 different formulations with effect from early 2025. Richter is going to legally challenge this decision.

Notes on GM profitability

Clean EBIT increased by mid single digit during the reported period as a result of increasing turnover and tight cost control implemented. Significantly higher development expenses and worsening exchange rate movements year-on-year were partly offset by the combined effects of an improving product mix, higher volumes and declining claw-back amounts.

Clean EBIT margin remained virtually unchanged in the first six months to June 2024 when compared to the base period.

5. Research and Development

Research and development have always played an important role in the Company’s life, with top priorities of research of original drug molecules, new product launches and innovation in the Company’s strategy since its foundation in 1901. Gedeon Richter Plc, with more than 1,200 employees in the field of research and development, remains the most significant pharmaceutical research base in the Central and Eastern European region. Pharmaceutical R&D at the Company embraces four strategic areas, notably recombinant biotechnological activities, research and development of new chemical entities (NCEs), late-stage women’s healthcare projects, and generic product developments.

5.1. R&D Activities Serving the Goals of Certain Business Units

In 2023 there were significant changes in the Company’s operation and governance model. The newly formed organization and the changed responsibilities did not leave the operation of the R&D organization untouched. R&D processes and decision points had to be adapted to the new operation based on Business Units. We successfully completed this work in the second half of the period under review, so the following chapters of the report will describe the work dedicated to the different business units. It is important to emphasize that the R&D Directorate continues to bear the responsibility for all original (CNS BU), generic (GM BU) and women healthcare (WHC BU) R&D projects. The two affiliate development units (in Poland and Romania) came under the direct professional management of the directorate, which serve with their resources of formulation development primarily the GM Business Unit’s projects. Finished dosage form development of the women healthcare and original projects continues to take place in Budapest. Global Medical Division and the Analytical Department of Biological Samples, both part of the Research and Development Directorate, continuously cooperated with all Business Units, including the Biotechnology Business Unit, and supported the latter's work in the implementation of clinical trials.

Based on the preliminary data of the Phase II study, Richter will not pursue further the development of RGH-706 in hyperphagia associated with Prader-Willi syndrome. Internal analyses of the accumulated clinical data are ongoing to identify other potential development opportunities with the molecule.

6. Corporate Matters

6.1. Information Regarding Richter Shares

Share Structure of the Company

There are no shares in issue that involve special control rights. Gedeon Richter Plc. has no shares whose market trading is not permitted. There is no restriction regarding the transfer of shares in issue representing the share capital. The Company is not aware of any agreement between shareholders that would result in restricting shares issued or the transfer of voting rights.

Each share with a face value of HUF 100 entitles the holder to one vote; however, the Statutes restrict the exercise of shareholders' rights by stipulating that at the AGM no shareholder shall exercise voting rights, in their own right or as a proxy of another shareholder, alone or together with other related person(s) in excess of 25 percent of the voting rights represented by the shareholders attending in person or by proxy.

Shares in issue

As of 1 January 2024, the number of ordinary shares comprising the Company's subscribed capital was 186,374,860. The number of shares did not change in the course of the reported period.

Share price performance

The closing price of shares as of 30 June 2024 was HUF 9,580 compared to HUF 8,900 as of 2 January 2024. Average monthly share prices in the first half 2024 varied between the minimum of HUF 9,216 per share (in April) and the maximum of HUF 9,722 per share (in February).

Market capitalization

The Company's market capitalisation linked to the performance of its share price on the Budapest Stock Exchange at the end of the reported period was HUF 1,786bn reflecting an approximately 10 percent increase in HUF terms when compared to its value recorded on 29 December 2023. Market capitalisation on 30 June 2024 in Euro terms was EUR 4.5bn.**Treasury shares**

The number of shares held by the Parent company in Treasury increased during the first half 2024.

	Reason of purchase	Number	Nominal value (HUF)	% as of share capital
Opening balance 1 January 2024		**3,190,418**	**319,041,800**	**1.712**
out of which owned by Parent Company		*3,190,418*	*319,041,800*	*1.712*
Share purchase		741,291	74,129,100	0.398
Shares of the employees share bonus that have not vested	Programme approved by NTCA*	12,429	1,242,900	0.007
Total share purchased		**753,720**	**75,372,000**	**0.404**
ESOT and other remuneration linked shares transferred		69,962	6,996,200	0.038
Total share used		**69,962**	**6,996,200**	**0.038**
Closing balance 30 June 2024		**3,874,176**	**387,417,600**	**2.079**
out of which Parent Company		*3,874,176*	*387,417,600*	*2.079*

Note: * National Tax and Customs Administration of Hungary

The total number of Company shares at Group level held in Treasury on 30 June 2024 was 3,874,176 out of which the Group's subsidiaries held a total of 0 ordinary Richter shares.

In accordance with a repurchase obligation related to employee share bonuses, the Company repurchased 12,429 shares from employees who resigned from the Company during the first six months 2024.

Based on a decision of the Board of Directors, 69,962 shares held by the Company in treasury were granted in the first half 2024 to employees participating in a bonus share programme and to other employees who rendered outstanding performance.

On 2 January 2024, following the expiry of the lock-up period the Company was able to remove all restrictions on 212,693 Richter ordinary shares granted to its employees on 20 December 2021, thereby enabling these shares to be traded..

Ownership structure

The shareholder structure on 30 June 2024 is presented in detail in the following table:

Ownership	Ordinary shares	Voting rights	Share capital
	Number	%	%
Domestic ownership	**63,895,934**	**35.01**	**34.28**
State ownership total	126	0.00	0.00
out of which Municipality	126	0.00	0.00
Institutional investors	55,806,984	30.58	29.94
out of which Maecenas Universitatis Corvini Foundation	18,637,486	10.21	10.00
out of which Mathias Corvinus Collegium Foundation	18,637,486	10.21	10.00
out of which Foundation for National Health and Education of Medical Doctors	9,777,658	5.36	5.25
Retail investors	8,088,824	4.43	4.34
International ownershp	**118,128,146**	**64.73**	**63.38**
Institutional investors	117,724,990	64.51	63.16
out of which FMR LLC	9,457,941	5.18	5.07
Retail investors	403,156	0.22	0.22
Treasury shares and shares transferred to ESOT*	**4,340,180**	**0.25**	**2.33**
Undisclosed ownership	**10,600**	**0.01**	**0.01**
Share capital	**186,374,860**	**100.00**	**100.00**

Note: * Treasury shares with exception of those owned by ESOT do not have voting rights attached.

Share buyback programme

On 4 April 2023, the Board of Directors of the Company, having considered shareholders' expectations, decided on a 12-month share buyback programme of up to a cumulative maximum amount of HUF 40 billion as part of shareholder remuneration in addition to the proposed dividend as previously announced. The decision was taken in accordance with the improving financial results and cash generation of the Company. The implementation of the share repurchase programme commenced on 6 April 2023, with the involvement of UniCredit Bank Hungary Zrt. and Raiffeisen Bank Zrt. as investment companies. Within the framework of the programme, a total of 4,080,882 shares were purchased on the Budapest Stock Exchange at an average price of HUF 8,829, reaching a total value of approximately HUF 36bn.

During the reported period the Company has purchased on the Budapest Stock Exchange 741,291 treasury shares within the share buyback programme .

6.2. Information Regarding Richter's Boards

On 26 February 2024 the Board of Directors informed the company's shareholders that Mr Erik Bogsch with effect from 1 March 2024 resigned from his position as Chairman of the Board of Gedeon Richter Plc., while remaining a member of the Board. The Board of Directors accepted the resignation at its regular meeting held on 26 February 2024.

The Board of Directors on its meeting held on 26 February 2024 elected Prof Dr E. Szilveszter Vizi as Chairman of the Board of Directors and also elected Dr Ilona Hardy Dr Pintérné as deputy Chairman of the Board of Directors with effect from 1 March 2024 for a period until the date of the AGM in 2027.

The AGM held on 25 April 2024 approved the re-election as members of the Board of Directors for a three-year-period until the 2028 AGM of the following:

Dr Nándor Pál Ács,
Mr Bálint Szécsényi and
Dr Anett Pandurics.

The AGM held on 25 April 2024 approved the re-election as members of the Supervisory Board for a three-year-period until the 2028 AGM of the following:

Dr Jonathán Róbert Bedros,
Mr Ferenc Sallai,
Dr Lívia Pavlik and
Dr Krisztina Gál.

The AGM held on 25 April 2024 approved the election as member of the Supervisory Board for a three-year-period until the 2028 AGM of

Mr André Martin Dale.

6.3. Dividend

Payout procedures as decided by the Board of Directors were published in an official announcement on 24 May 2024. The starting date for distributing dividend payments was 13 June 2024.

Further information on dividend can be found on page 54 in Note 16.

6.4. Extraordinary Announcements

Business related

2024.01.29	Richter becomes strategic investor of Formycon via equity investment
2024.03.06	Richter acquires HELM AG's entire stake in Richter-Helm BioTec and Richter-Helm BioLogics joint ventures in Germany
2024.05.03	Richter has submitted an offer and entered into negotiations to acquire certain assets assets from Mithra Pharmaceuticals in Belgium
2024.05.31	Acquisition of biotechnology assets in Germany closed
2024.06.11	Richter agreed to acquire certain assets from Mithra Pharmaceuticals
2024.06.19	Richter acquires BCI Pharma
2024.07.18.	Submission to European Medicines Agency for biosimilar Denosumab in multiple indications

AGM related

2024.03.25	AGM - Invitation
2024.03.25	Board of Directors' proposal to the 2024 Annual General Meeting
2024.04.03	AGM - Proposals I.
2024.04.03	AGM - Proposals II.
2024.04.03	AGM - Proposals III.
2024.04.25	AGM resolutions
2024.04.26	Corporate Governance Report from the year of 2023
2024.04.26	Remunation report of Gedeon Richter Plc from the year of 2023 approved by the AGM 2024
2024.04.26	Remunation policy (2021-2024); Remunation policy (2025-2028)
2024.04.26	Annual Report approved by Gedeon Richter Plc.'s Annual General Meeting on April 25, 2024 (ZIP)
2024.05.24	Payment of dividends
2024.05.31	Statutes

Legal, regulatory

2024.01.02	Voting rights, registered capital
2024.01.02	Expiry of lock-up period
2024.01.03	Transactions with Treasury Shares
2024.01.04	Transactions with Treasury Shares
2024.01.05	Transactions with Treasury Shares
2024.01.08	Transactions with Treasury Shares
2024.01.09	Transactions with Treasury Shares
2024.01.10	Transactions with Treasury Shares
2024.01.11	Transactions with Treasury Shares
2024.01.12	Transactions with Treasury Shares
2024.01.15	Transactions with Treasury Shares
2024.01.16	Transactions with Treasury Shares
2024.01.17	Transactions with Treasury Shares
2024.01.18	Transactions with Treasury Shares
2024.01.19	Transactions with Treasury Shares
2024.01.22	Transactions with Treasury Shares
2024.01.23	Transactions with Treasury Shares
2024.01.24	Transactions with Treasury Shares

2024.01.25	Transactions with Treasury Shares
2024.01.26	Transactions hithű Treasury Shares
2024.01.29	Transactions with Treasury Shares
2024.01.30	Transactions with Treasury Shares
2024.01.31	Transactions with Treasury Shares
2024.02.01	Transactions with Treasury Shares
2024.02.01	Voting rights, registered capital
2024.02.02	Transactions with Treasury Shares
2024.02.05	Transactions with Treasury Shares
2024.02.06	Transactions with Treasury Shares
2024.02.07	Transactions with Treasury Shares
2024.02.20	Transactions with Treasury Shares
2024.02.29	Transactions with subsidiaries in the twelve months to December 2023
2024.03.01	Transactions with Treasury Shares
2024.03.01	Voting rights, registered capital
2024.03.22	Transactions with Treasury Shares
2024.04.02	Voting rights, registered capital
2024.05.02	Voting rights, registered capital
2024.05.14	Transactions with Treasury Shares
2024.05.14	Transactions with subsidiaries in the three months to March 2024
2024.05.23	Transactions with Treasury Shares
2024.05.31	Divident Payment
2024.05.31	Voting rights, registered capital
2024.06.03	Transactions with Treasury Shares
2024.06.28	Transactions with Treasury Shares
2024.06.28.	Transactions with Treasury Shares

Other announcements

2024.01.26	Changes in supplementary pharmaceutical tax regulation
2024.02.26	Changes in the Board of Directors of Gedeon Richter Plc.
2024.05.22	Change in the Leadership team of Gedeon Richter Plc.

7. Risk Management

The risk management activity is an integral part of Richter's activities and corporate governance system. It is closely connected to the realization of the Company's strategic goals. The purpose of the risk management is the timely identification, evaluation and management of risks that threaten the stable operation of Richter and the achievement of its goals with cost-effective measures. To achieve this, Richter introduced a holistic and integrated risk management system, which examines and manages all of the company's risks together with their interrelationships. The Investment Committee is held on a weekly basis, where financial risks are regularly reviewed. To support business continuity, the Company operates an integrated business continuity management system, which it continuously develops.

7.1. Financial risks

Main risk areas	Risks	Controls	Valuation
Liquidity risk	Company cannot fulfill its payment obligations or only at cost of significant financial losses.	Daily monitoring, separate liquidity portfolio, short- and long-term planning, strongly positive CF expectation, cash pool, repo, option for taking a loan.	Negligible ⇨
Currency risk	Significant part of cash flow is in foreign currency; profit and balance sheet are exposed to changes in FX rates; high expected volatility of FX rate changes; main exposures in USD, RUB, EUR.	Hedging transactions; natural hedges; usage of limits; RUB - hedging with derivative transactions is not possible in the current market situation, but the risk can be mitigated with other methods (e.g. discounting).	Very high ⇨
Interest rate risk	The yield and value of interest-bearing assets may change due to changes of interest rates	Interest rate swaps; duration limits; tradeable securities valued at fair value (except for short term government bonds); no hidden interest rate risk.	Middle ⇨
Credit risk of customers	Non-fulfillment or not timely fulfillment of payment obligations by the customers.	Risk management supported by a centralized IT system; rules; limits; monitoring; collaterals like bank guarantee, credit insurance; export credit insurance program for insurable non-market countries, including Russia.	Low ⇧
Credit risk of investment partners	Significant negative changes in the position of our investment partners may cause losses (non-payment, value loss).	Limit system (based on credit rating assessment); daily monitoring; diversification; the portfolio is diversified and stable; tradeable securities are valued at fair value (except for short term government bonds), there is no hidden credit risk.	Middle ⇨
Inflation related risk	Margins may narrow due to cost inflation, and some products may even become unprofitable. A significant part of products have fixed prices, which reduces the possibility of passing on expense increases.	Increase sales prices (where possible); improve efficiency; find cheaper sources of purchase; conclude longer-term agreements, cover energy costs.	High ⇩

Negligible
Low
Middle
High
Very high

7.2. Hedging Policy

The management of the foreign exchange rate risk is based on the strategy approved by the Board of Directors. The financial area regularly analyzes the netted group-level risk exposure and the available hedging options.

The Group uses only standard derivative instruments for hedging purposes. Hedging transactions are entered into when the risk situation and potential benefits make it reasonable; only the Parent Company is entitled to conclude them..

Hedging deal	Purpose of coverage	Open forward portfolio
FX	The Group applies hedge accounting in accordance with IFRS9 for a part of the transactions covering sales income. In H1 2024, we also regularly carried out currency hedging operations, and at the end of the period, with regard to the USD revenues, the Group registers open rolling hedging transactions for a six-quarter period (Q2 2023 – Q3 2025) under hedge accounting.	USDHUF currency pair in the amount of USD 363.75m
FX	Non hedge accounting - to mitigate the currency revaluation effect in the financial result.	USDHUF currency pair in the amount of USD 21m and EURHUF currency pair in the amount of EUR 56.6m
Energy	From the beginning of 2023, the Group started to hedge the price and FX volatility of gas purchases linked to TTF's market reference under IFRS9 hedge accounting. The open forward position covers purchases for the calendar year of 2024.	nominal value of EUR 8.88m

7.3. Main strategic and operational risks

The Company is constantly developing its integrated operational risk management system, the essential elements of which are the assessment of strategic risks, the self-assessment of the risks and controls covering the operational processes of Richter.

Strategic risks	Controls	Valuation
Outstanding contribution of cariprazine to the turnover and profits of the Company (concentration risk)	Development of a new tracking molecule with our US partner; geographic expansion of sales; ensuring the continuity of production USA	High ⇩
Risks related to the achievement of the strategic goals of the Biotechnology BU	Development of medical and regulatory fields; strict monitoring of clinical trials and CROs, contract manufacturing - increase of capacity; utilization; improve the focus of the product selection strategy	High ⇨
Risks related to achieving the strategic goals of the General Medicine BU	Development of well-selected products; strong project management; improvement of coverage indicators; product diversification; Life Cycle Management framework; special attention in the pharmacovigilance system	High ⇧
Direct and indirect risks caused by the Russian-Ukrainian war	New sources of supply; monitoring of risks and sanctions, ensuring continuous compliance on the field of logistics, production and finance; proactive preparation for the occurrence of risk events	High ⇩

Operational risks	Controls	Valuation
Cyber risk	Operation and development of the IT security area; education, increase f risk awareness (main focus); multifactor authentication; monitoring and handling of incidents; strong external protection, data governance model	Very high ⇨
Risk unfavorable changes in the price support system, price erosion, risks of increasing claw-back taxes	Focusing the introduction of new products on the product range less exposed to promotion; a gradual price increase at products with non-fixed price; closer monitoring of claw-back payments; measuring and strengthening product profitability; selective withdrawal from the sale of certain products	High ⇨
Ensuring qualified workforce	Development of employer branding; constructions helping to retain the workforce; training collaborations with educational institutions; adapting to labor market needs; fluctuation monitoring; workforse replacement planning, competency planning; welfare and health programs; efficiency improvement	High ⇧
Risk of quality/absence of data used for decision-making and operation	The activity of a unit established to support data-based decision-making and to make available corporate data assets for the implementation of data-driven operations; supporting IT developments	High ⇩

Negligible
Low
Middle
High
Very high

8. Litigation Proceedings

Bayer AG has requested preliminary injunction and initiated court procedures claiming infringement in Bulgaria, Czech Republic, Estonia, Poland, Latvia, Hungary, Slovakia, Romania, on the bases of its indication patent EP 1845961 against the Company due to entering certain markets with Richter's generic product containing Rivaroxaban as active pharmaceutical ingredient. As a result of those procedures in certain Countries Richter was banned from the market, while in other Countries the court grated limited injunction, furthermore in some Countries the court refused Bayer AG's request. Procedures are ongoing and no final decision has been taken so far.

9. Sustainibility Review

9.1. Highlights for the first half of 2024

Richter Gedeon Plc. is subject to the European Union's Corporate Sustainability Reporting Directive (CSRD), which came into force on 1 January 2024. This requires us to disclose sustainability-related information in accordance with the European Sustainability Reporting Standards (ESRS). In line with this obligation, our disclosure practices from the year 2025 will be aligned with the requirements of the CSRD and ESRS. In addition, we will add voluntary standards and metrics to our disclosures to increase transparency and accountability. The list of material topics to be disclosed is determined by the outcome of our double materiality assessment (DMA). This process will be completed in August 2024.

9.2. Environment and climate change

As the next step in our climate protection efforts, we have launched a project to develop our carbon reduction strategy. The project aims to set group-level targets to meet the international climate goals (Paris Agreement). To do this, we will follow the SBTi (Science Based Target initiative) guidelines. Data gaps are currently being mapped.

To facilitate modern waste collection and processing, a new central waste yard has been completed at the Budapest site, which is expected to be commissioned early in the second half of 2024. The new waste yard will allow for more effective waste sorting and collection using new equipment. At the same time some of the old yard collection points will be dismantled.

9.3. Employees and communities

The update of Richter's diversity policy was accepted in 2023. In 2024, we made steps to consciously address diversity and inclusion at a high level. We laid down the foundations for the company's diversity strategy. In this process, four focus themes were identified that are relevant to Richter's day-to-day operations: working together in a four-generation company; maximising women's career paths; value-creating collaboration between physical and mental workers; and cultural diversity in different geographical locations. This year, we are reviewing our internal processes (e.g., recruitment process, existing relevant policies) from a DEI (diversity, equity and inclusion) point of view. To gain a better understanding of the barriers to intergenerational collaboration, we organised an employee forum last year and in January of 2024 we produced a podcast for Richter employees to raise awareness, based on the previous event's takeaways. We also joined three professional organisations (Employers' Equal Opportunities Forum, Hungarian Business Leaders Forum - European Diversity Charter Hungary, and the Open We Are Foundation) in order to learn from and collaborate with other companies to improve our good practices.

At the beginning of the year, negotiations on our collective agreement were concluded in cooperation with the trade union (VDSz Gyógyszergyári Szakszervezet). Under this agreement, a wage increase came into effect at our Hungarian sites from 1 March 2024. We recognise the dedication and professionalism of our employees with an average pay increase of 10.3%.

In June 2024, we inaugurated a new sustainable head office building in Budapest. The 17,400 square metre, six-storey building provides an inspiring and comfortable working environment for more than 400 employees. The LEED Gold (certification pending) building is a model for future architectural projects, thanks to the technologies used and its reduced ecological footprint. Ground-source heat pumps harness the earth's heat to provide heating in winter and cooling in summer, minimising the building's energy requirements. The green surfaces in and around the building improve the building's microclimate and contribute to local biodiversity, while the green roof garden contributes to sustainable water management.

9.4. Community involvement

Healthcare and education are two areas where we can contribute our expertise in line with our corporate social responsibility policy – they are also integral to the Company's core business of drug discovery and manufacturing. Supporting healthcare and raising health awareness is part of our mission, and we also aim to ensure the supply of new employees by supporting education. In addition to the above, women-focused programmes also play a key role in Richter's social commitment, with the aim of protecting women's health and increasing women's recognition and spiritual and social well-being. In the first half of 2024, our Company supported initiatives in the fields of health, social health awareness, science education and, in particular, women's health and social and professional recognition by approximately HUF 1.5 billion.

In cooperation with the Hungarian Charity Service of the Order of Malta (Magyar Máltai Szeretetszolgálat) and the Association of Hungarian Health Visitors (Magyar Védőnők Egyesülete), we launched our Richter RAJT education programme at the end of 2023, which aims to provide children in Hungarian municipalities living in extreme poverty with a comprehensive sex education. The initiative raises awareness among students (both girls and boys) on important topics such as family planning, intimate hygiene, responsible relationships, sexually transmitted diseases, the importance of health screening, contraception and abortion prevention. Raising awareness and promoting preventive thinking can help to prevent many health problems, thus contributing to a better quality of life. So far, more than 700 students have attended the interactive sessions in four locations. In addition, teachers have benefited from workshops with experts to answer their questions.

Richter has long been looking for an international opportunity to step outside its current CSR activities and help in the developing world. In line with this ambition, we have become a major supporter of the project of the Hungary-based The Close to Africa Foundation (Közel Afrikához Alapítvány), who are building a "House of Hope" for disadvantaged and vulnerable women in Bamako, the capital of Mali. The centre will provide psychological, legal and health counselling, as well as educational programmes for women in need. Richter is providing a significant part of the construction costs and operating support. The foundation stone for the Gedeon Richter House of Hope was laid in early February 2024 and the house is expected to open in 2025.

9.5. Access to Health

Richter's strategic goal is to become Europe's leading player in the WHC market by the end of the decade. We have completed a number of transactions in recent years to expand our WHC product portfolio, and in the first half of 2024 we took the first steps towards building Richter's independent original WHC research capabilities. The acquisitions of Mithra Pharmaceuticals SA and certain assets of Mithra Recherche et Développement SA, as well as the original research company BCI Pharma, represent an exceptional opportunity to further strengthen Richter's strategic business to serve patients as widely as possible. With these new acquisitions, Richter will cover the entire value chain from original research to commercialisation and will be able to offer its own specialised gynaecological product portfolio on all continents.

9.6. Anti-corruption; compliance

Our Company expects the highest ethical standards and is committed to complying with all local and international anti-bribery and anti-corruption laws and regulations that apply to its activities worldwide. Therefore, our whistleblower system will be extended to territories outside the European Union in 2024: to Latin American countries and to Australia. Preparations for the expansion were made in the first half of 2024, with activation expected in the second half of 2024. In the first half of 2024, our online whistleblowing system, which is available in several languages, received 5 reports, of which 0 were ethical misconducts.

A comprehensive partner due diligence project was launched in the first half of the year. The aim of this project is to conduct a compliance due diligence of the Company's potential and certain existing partners, both at parent company and network level, using a common framework. The project will develop a common set of procedures, policies and questionnaires.

A project to develop an international promotional material approval system has also been launched. The aim of the system is to standardise the global approval process for promotional material within the Company, defining the responsibilities for each step of the approval process. The foundations of the regulatory structure underlying the approval process were laid earlier this year.

II. Condensed Consolidated Financial Statements Prepared in Accordance with IFRS for the Period Ended 30 June 2024

Condensed Consolidated Income Statement

for the period ended 30 June

	Notes	2024 Not audited HUFm	2023 Not audited HUFm
Revenues	**3**	**419,693**	**413,436**
Cost of sales	3	(127,722)	(157,129)
Gross profit	3	**291,971**	**256,307**
Sales and marketing expenses	3	(80,801)	(75,286)
Administration and general expenses	3	(26,818)	(25,530)
Research and development expenses	3	(45,367)	(39,353)
Other income	4	9,535	5,370
Other expenses	4	(22,659)	(26,399)
Reversal of impairment/(impairment) on financial and contract assets	4	624	(96)
Profit from operations		**126,485**	**95,013**
Finance income	5	52,515	52,384
Finance costs	5	(28,273)	(77,245)
Net financial income	**5**	**24,242**	**(24,861)**
Share of profit of associates and joint ventures	13	5,902	2,702
Profit before income tax		**156,629**	**72,854**
Income tax	6	(17,822)	(3,809)
Profit for the period		**138,807**	**69,045**
Profit attributable to			
Owners of the parent		138,215	67,936
Non-controlling interest		592	1,109
Earnings per share (HUF)	7		
Basic and diluted		756	365

The notes on pages 34-58 form an integral part of the Condensed Consolidated Financial Statements.

Condensed Consolidated Statement of Comprehensive Income

for the period ended 30 June

	Notes	2024 Not audited HUFm	2023 Not audited HUFm
Profit for the period		**138,807**	**69,045**
Items that will not be reclassified to profit or loss (net of tax)			
Actuarial gain on retirement defined benefit plans		177	-
Changes in the fair value of equity investments at fair value through other comprehensive income		1,736	(2,755)
		1,913	**(2,755)**
Items that may be subsequently reclassified to profit or loss (net of tax)			
Exchange differences arising on translation of subsidiaries	13	(2,573)	(4,779)
Exchange differences arising on translation of associates and joint ventures		(59)	113
Change in fair value of hedging instruments recognised in OCI	9	(1,730)	14,217
Hedging (gain) reclassified to profit or loss		(5,735)	(6,353)
Changes in fair value of debt instruments at FVOCI		506	(534)
		(9,591)	**2,664**
Other comprehensive income for the period		**(7,678)**	**(91)**
Total comprehensive income for the period		**131,129**	**68,954**
Attributable to:			
Owners of the parent		130,291	68,633
Non-controlling interest		838	321

The notes on pages 34-58 form an integral part of the Condensed Consolidated Financial Statements.

Condensed Consolidated Balance Sheet – Assets

	Notes	30 June 2024 Not audited HUFm	31 December 2023 Audited HUFm
Non-current assets			
Property, plant and equipment	10	359,921	347,394
Goodwill	11	73,953	31,903
Other intangible assets	12	261,514	230,383
Investments in associates and joint ventures	13	16,625	15,177
Non-current financial assets at amortised cost	8	1,190	4,120
Non-current financial assets at FVTPL	8	74,556	75,839
Non-current financial assets at FVOCI	8	68,107	71,739
Derivative financial instruments	9	17,475	16,327
Deferred tax assets		32,213	29,244
Long-term receivables		7,255	4,178
		912,809	**826,304**
Current assets			
Inventories		205,752	177,767
Trade receivables		234,136	204,968
Contract assets		8,483	8,103
Other current assets		36,305	44,538
Current financial assets at amortised cost	8	934	6,239
Current financial assets at FVOCI	8	-	1,454
Derivative financial instruments	9	1,728	9,662
Current tax asset		1,626	1,689
Cash and cash equivalents		56,920	80,493
		545,884	**534,913**
Total assets		**1,458,693**	**1,361,217**

The notes on pages 34-58 form an integral part of the Condensed Consolidated Financial Statements.

Condensed Consolidated Balance Sheet – Equity and liabilities

	Notes	30 June 2024 Not audited HUFm	31 December 2023 Audited HUFm
Capital and reserves			
Equity attributable to owners of the parent			
Share capital		18,638	18,638
Treasury shares		(36,892)	(29,982)
Share premium		15,214	15,214
Capital reserves		3,475	3,475
Foreign currency translation reserves		46,655	49,533
Revaluation reserves for financial assets at FVOCI		4,491	1,999
Cash-flow hedge reserve		(919)	6,546
Retained earnings		1,118,947	1,065,391
		1,169,609	**1,130,814**
Non-controlling interest	14	3,606	11,767
		1,173,215	**1,142,581**
Non-current liabilities			
Borrowings	19	357	182
Deferred tax liability		11,285	3,824
Non-current financial liabilities at FVTPL	8	58,092	54,467
Derivative financial instruments	9	13,719	11,413
Lease liability		14,856	13,817
Other non-current liabilities and accruals		13,449	13,866
Provisions	15	6,418	6,559
		118,176	**104,128**
Current liabilities			
Borrowings	19	35,624	-
Trade payables		45,316	51,301
Contract liabilities		1,741	2,347
Current tax liabilities		14,663	1,974
Current financial liabilities at FVTPL	8	2,689	2,722
Derivative financial instruments	9	2,138	935
Lease liability		4,907	4,428
Other current liabilities and accruals		58,716	47,840
Provisions	15	1,508	2,961
		167,302	**114,508**
Total equity and liabilities		**1,458,693**	**1,361,217**

The notes on pages 34-58 form an integral part of the Condensed Consolidated Financial Statements.

Condensed Consolidated Statement of Changes in Equity

	Notes	Share capital	Share premium	Capital reserves	Treasury shares	Revaluation reserve for financial assets at FVOCI	Foreign currency translation reserves	Cash-flow hedge reserve	Retained earnings	Equity attributable to owners of the parent	Non-controlling interest	Total
		HUFm	HUFm	HUFm	HUFm	HUFm	HUFm	HUFm	HUFm	HUFm	HUFm	HUFm
Restated balance at 1 January 2023*		**18,638**	**15,214**	**3,475**	**(2,123)**	**(339)**	**47,846**	**820**	**979,870**	**1,063,401**	**10,446**	**1,073,847**
Profit for the year		-	-	-	-	-	-	-	67,936	67,936	1,109	69,045
Exchange differences arising on translation of subsidiaries		-	-	-	-	-	(3,991)	-	-	(3,991)	(788)	(4,779)
Exchange differences arising on translation of associates and joint ventures	13	-	-	-	-	-	113	-	-	113	-	113
Changes in the fair value of financial assets at FVOCI		-	-	-	-	(3,289)	-	-	-	(3,289)	-	(3,289)
Change in fair value of hedging instruments recognised in OCI		-	-	-	-	-	-	14,217	-	14,217	-	14,217
Hedging (gain) reclassified to profit or loss		-	-	-	-	-	-	(6,353)	-	(6,353)	-	(6,353)
Comprehensive income for the period ended 30 June 2023		**-**	**-**	**-**	**-**	**(3,289)**	**(3,878)**	**7,864**	**67,936**	**68,633**	**321**	**68,954**
Purchase of treasury shares		-	-	-	(7,849)	-	-	-	-	(7,849)	-	(7,849)
Transfer of treasury shares		-	-	-	(49)	-	-	-	49	-	-	-
Recognition of share-based payments		-	-	-	-	-	-	-	944	944	-	944
Ordinary share dividend for 2022	16	-	-	-	-	-	-	-	(72,686)	(72,686)	-	(72,686)
Dividend paid to non-controlling interest		-	-	-	-	-	-	-	-	-	(91)	(91)
Sale of subsidiary		-	-	-	-	-	-	-	-	-	99	99
Transactions with owners in their capacity as owners for the period ended 30 June 2023		**-**	**-**	**-**	**(7,898)**	**-**	**-**	**-**	**(71,693)**	**(79,591)**	**8**	**(79,583)**
Restated balance at 30 June 2023*		**18,638**	**15,214**	**3,475**	**(10,021)**	**(3,628)**	**43,968**	**8,684**	**976,113**	**1,052,443**	**10,775**	**1,063,218**

* At the end of 2023, in line with the change of the accounting policy, the deferred tax related to investment tax benefits was recognised retrospectively as of 31 December 2022.

The notes on pages 34-58 form an integral part of the Condensed Consolidated Financial Statements.

Condensed Consolidated Statement of Changes in Equity

	Notes	Share capital	Share premium	Capital reserves	Treasury shares	Revaluation reserve for financial assets at FVOCI	Foreign currency translation reserves	Cash-flow hedge reserve	Retained earnings	Equity attributable to owners of the parent	Non-controlling interest	Total
		HUFm	HUFm	HUFm	HUFm	HUFm	HUFm	HUFm	HUFm	HUFm	HUFm	HUFm
Balance at 1 January 2024		**18,638**	**15,214**	**3,475**	**(29,982)**	**1,999**	**49,533**	**6,546**	**1,065,391**	**1,130,814**	**11,767**	**1,142,581**
Profit for the period		-	-	-	-	-	-	-	138,215	138,215	592	138,807
Exchange differences arising on translation of subsidiaries		-	-	-	-	-	(2,819)	-	-	(2,819)	246	(2,573)
Exchange differences arising on translation of associates and joint ventures	13	-	-	-	-	-	(59)	-	-	(59)	-	(59)
Actuarial gain on retirement defined benefit plans		-	-	-	-	-	-	-	177	177	-	177
Changes in the fair value of financial assets at FVOCI		-	-	-	-	2,492	-	-	(250)	2,242	-	2,242
Change in fair value of hedging instruments recognised in OCI		-	-	-	-	-	-	(1,730)	-	(1,730)	-	(1,730)
Hedging gain reclassified to profit or loss		-	-	-	-	-	-	(5,735)	-	(5,735)	-	(5,735)
Total comprehensive income for the period ended 30 June 2024		**-**	**-**	**-**	**-**	**2,492**	**(2,878)**	**(7,465)**	**138,142**	**130,291**	**838**	**131,129**
Purchase of treasury shares		-	-	-	(6,936)	-	-	-	-	(6,936)	-	(6,936)
Transfer of treasury shares		-	-	-	26	-	-	-	(26)	-	-	-
Recognition of share-based payments		-	-	-	-	-	-	-	1,098	1,098	-	1,098
Ordinary share dividend for 2023	16	-	-	-	-	-	-	-	(78,837)	(78,837)	-	(78,837)
Dividend paid to non-controlling interest		-	-	-	-	-	-	-	-	-	(9)	(9)
Acquisition of non-controlling interest		-	-	-	-	-	-	-	(6,821)	(6,821)	(8,990)	(15,811)
Transactions with owners in their capacity as owners for the period ended 30 June 2024		**-**	**-**	**-**	**(6,910)**	**-**	**-**	**-**	**(84,586)**	**(91,496)**	**(8,999)**	**(100,495)**
Balance at 30 June 2024		**18,638**	**15,214**	**3,475**	**(36,892)**	**4,491**	**46,655**	**(919)**	**1,118,947**	**1,169,609**	**3,606**	**1,173,215**

The notes on pages 34-58 form an integral part of the Condensed Consolidated Financial Statements.

Condensed Consolidated Cash-Flow Statement

for the period ended 30 June

	Notes	2024 Not audited HUFm	2023 Not audited HUFm
Operating activities			
Profit before income tax		156,629	72,854
Depreciation and amortisation		23,287	24,445
Non-cash items		(5,413)	(4,328)
Net interest and dividend income	5	(2,022)	(4,807)
Other items		0	351
Interest paid		(7,576)	(8,623)
Income tax paid	6	(7,432)	(5,200)
Gain on disposal of subsidiaries		-	(12,000)
Net cash-flow from operating activities before changes in working capital		**157,473**	**62,692**
Movements in working capital		*(36,512)*	*(11,137)*
(Increase)/decrease in trade and other receivables		(11,390)	4,792
(Increase)/decrease in inventories		(28,217)	925
Increase/(decrease) in payables and other liabilities		3,095	(16,854)
Net cash-flow from operating activities		**120,961**	**51,555**
Cash-flow from investing activities			
Payments for property, plant and equipment*		(19,709)	(23,065)
Payments for intangible assets*		(1,678)	(24,060)
Proceeds from disposal of property, plant and equipment		1,210	1,103
Payments to acquire financial assets		(32,243)	(31,819)
Proceeds on sale or redemption on maturity of financial assets		49,529	67,440
Disbursement of loans net		114	23,083
Interest received	5	10,101	13,046
Dividend received	5	7	5
Net cash outflow on purchase of group of assets	17	(24,090)	(14,142)
Net cash outflow on acquisition of subsidiaries	17	(75,047)	-
Net cash inflow from disposal of subsidiaries		-	11,395
Net cash-flow to investing activities		**(91,806)**	**22,986**
Cash-flow from financing activities			
Purchase of treasury shares		(6,936)	(7,849)
Dividend paid	16	(78,846)	(72,777)
Principal elements of lease payments		(1,958)	(2,529)
Repayment of borrowings	19	(105,011)	(15,792)
Proceeds from borrowings	19	139,983	15,792
Net cash-flow to financing activities		**(52,768)**	**(83,155)**
Net decrease in cash and cash equivalents		**(23,613)**	**(8,614)**
Cash and cash equivalents at beginning of year		**80,493**	**79,719**
Effect of foreign exchange rate changes on cash and cash equivalents		40	(33)
Cash and cash equivalents at the end of the period		**56,920**	**71,072**

* The Payments for property plant and equipment and the Payments for intangible assets cannot be directly reconciled to the Note 10 Transfers and capital expenditure and Note 12 Additions, because the latter one contains non-material, non-cash addition of the assets, including transfers.

The notes on pages 34-58 form an integral part of the Condensed Consolidated Financial Statements.

Notes to the Condensed Consolidated Financial Statements

1. General background

1.1 Legal status and nature of operations

Gedeon Richter Plc. ("the Company"/"Parent Company"), the immediate parent of the Group (consisting of the Parent Company and its subsidiaries), a manufacturer of pharmaceutical products based in Budapest, was established first as a Public Limited Company in 1923. The predecessor of the Parent Company was founded in 1901 by Mr Gedeon Richter, when he acquired a pharmacy. The Company is a public limited company, which is listed on Budapest Stock Exchange. The Company's headquarter is in Hungary and its registered office is at Gyömrői út 19-21, 1103 Budapest.

1.2 Basis of preparation

The Condensed Consolidated Interim Financial Statements of Richter Group for the period ended 30 June 2024 have been prepared in accordance with Accounting Standard IAS 34 Interim Financial Reporting. The Condensed Consolidated Financial Statements comply with the Hungarian Accounting Law on consolidated financial statements, which refers to the IFRS as endorsed by the EU.

The interim report has not been audited and does not include all the notes of the type normally included in an annual financial report.

The report is to be read in conjunction with the Annual report for the year ended 31 December 2023 and any public announcements made by Richter during the interim reporting period..

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period.

2. Significant changes in the current reporting period

- The AGM approved the payment of HUF 78.8bn dividend from 2023 net profit (see Note 16).
- On 11 June 2024, Gedeon Richter announced that it acquired 100% of the shares in Estetra SRL („Estetra") and Neuralis SA („Neuralis") from Mithra Pharmaceuticals SA (see Note 17).
- On 19 June 2024 Richter announced that it has acquired BCI Pharma, a Belgium-based privately-owned biotech company, carrying out innovative research activity in a variety of Women's Health conditions (see Note 17).
- On 6 March 2024 Richter announced that it acquired 50% stake in Richter-Helm BioTec GmbH & Co. KG and 30% stake in Richter-Helm BioLogics GmbH & Co. KG. to become 100% owner of both companies. The transaction was closed on 31 May 2024 (see Note 17).

3. Segment Information

Operating segments are reported in a manner consistent with the internal reporting provided to the Board of Directors as chief operating decision-makers. The Board of Directors is responsible for allocating resources and assessing performance of the operating segments and makes strategic decisions.

Management has determined the operating segments based on the reports prepared on an IFRS basis and reviewed by the Board of Directors (Chief Operating Decision Makers) that are used to make strategic decisions. From a management point of view, the Group can be divided into two main segments, with several business units below them:

a) Pharma Segment:

- Women's Healthcare (WHC)
  By addressing unmet needs and staying ahead of innovation we aim to become the leading provider of pharmaceutical products for European women by the end of the decade.
- Neuropsychiatry (CNS)
  Leveraging our world class early phase R&D capability in the central nervous system domain we are building a pipeline of small molecule drug candidates mainly in the field of neuropsychiatry.
- Biotechnology (BIO)
  Leverage our biotechnology platform to develop and manufacture biosimilar drugs for global markets.
- General Medicines (GM)
  Comprises our established and generic portfolio in various therapeutic areas in the Central and Eastern European regions.
- Other pharma

b) Other segment includes the remaining wholesale and retail business of the Group and all other activities.

3.1 Business segments

for the period ended 30 June

	Neuropsychiatry (CNS) 6 months to June HUFm		General Medicines (GM) 6 months to June HUFm		Women's Healthcare (WHC) 6 months to June HUFm		Biotechnology (BIO) 6 months to June HUFm		Pharma other 6 months to June HUFm		Total 6 months to June HUFm	
	2024	**2023**	**2024**	**2023**	**2024**	**2023**	**2024**	**2023**	**2024**	**2023**	**2024**	**2023**
Revenues	109,418	89,410	121,420	114,560	149,519	129,738	26,521	21,305	6,501	7,126	413,379	362,139
Cost of sales	(782)	(515)	(54,517)	(51,251)	(45,520)	(40,330)	(16,799)	(12,896)	(6,450)	(5,801)	(124,068)	(110,793)
Gross profit	108,636	88,895	66,903	63,309	103,999	89,408	9,722	8,409	51	1,325	289,311	251,346
Sales and marketing expenses	(2,087)	(1,597)	(25,912)	(24,268)	(46,914)	(42,227)	(3,618)	(2,924)	(933)	(664)	(79,464)	(71,680)
Administration and general expenses	(500)	(354)	(10,157)	(9,944)	(12,503)	(10,296)	(2,111)	(2,029)	(543)	(568)	(25,814)	(23,191)
Research and development expenses	(16,593)	(12,253)	(5,629)	(4,318)	(6,449)	(9,034)	(16,696)	(13,748)	-	-	(45,367)	(39,353)
Claw-back	(639)	(298)	(1,412)	(2,070)	(3,265)	(2,904)	(387)	(280)	-	-	(5,703)	(5,552)
Milestone	50	81	-	-	118	8	2,511	508	-	-	2,679	597
Clean EBIT	88,867	74,474	23,793	22,709	34,986	24,955	(10,579)	(10,064)	(1,425)	93	135,642	112,167

Ratios	%	%	%	%	%	%	%	%	%	%	%	%
Gross margin	99.3	99.4	55.1	55.3	69.6	68.9	36.7	39.5	0.8	18.6	70.0	69.4
Clean EBIT margin	81.2	83.3	19.6	19.8	23.4	19.2	-39.9	-47.2	-21.9	1.3	32.8	31.0

	Pharmaceuticals total 6 months to June HUFm		Other 6 months to June HUFm		Eliminations 6 months to June HUFm		Group total 6 months to June HUFm	
	2024	**2023**	**2024**	**2023**	**2024**	**2023**	**2024**	**2023**
Revenues	413,379	362,139	12,399	59,076	(6,085)	(7,779)	419,693	413,436
Cost of sales	(124,068)	(110,793)	(9,557)	(53,981)	5,903	7,645	(127,722)	(157,129)
Gross profit	289,311	251,346	2,842	5,095	(182)	(134)	291,971	256,307
Sales and marketing expenses	(79,464)	(71,680)	(1,337)	(3,606)	-	-	(80,801)	(75,286)
Administration and general expenses	(25,814)	(23,191)	(1,004)	(2,339)	-	-	(26,818)	(25,530)
Research and development expenses	(45,367)	(39,353)	-	-	-	-	(45,367)	(39,353)
Claw-back	(5,703)	(5,552)	-	-	-	-	(5,703)	(5,552)
Milestone	2,679	597	-	-	-	-	2,679	597
Clean EBIT	135,642	112,167	501	(850)	(182)	(134)	135,961	111,183

Ratios	%	%	%	%	%	%	%	%
Gross margin	70.0	69.4	22.9	8.6	3.0	1.7	69.6	62.0
Clean EBIT margin	32.8	31.0	4.0	-1.4	3.0	1.7	32.4	26.9

3.2 Entity wide disclosures

The external customers of the Group are domiciled in the below presented regions:

2024 **6 months to June**	**Europe** HUFm	**APAC** HUFm	**North America** HUFm	**Latin America** HUFm	**Other countries** HUFm	**Total revenues** HUFm
Timing of revenue recognition						
At a point in time	242,616	27,822	111,936	18,297	4,400	405,071
Over time	8,213	1,698	4,521	-	190	14,622
Revenues	**250,829**	**29,520**	**116,457**	**18,297**	**4,590**	**419,693**
Total assets	1,416,568	15,654	1,082	25,389	-	1,458,693
Capital expenditure	21,054	249	-	84	-	21,387

2023 **6 months to June**	**Europe** HUFm	**APAC** HUFm	**North America** HUFm	**Latin America** HUFm	**Other countries** HUFm	**Total revenues** HUFm
Timing of revenue recognition						
At a point in time	269,530	20,020	93,798	14,138	4,158	401,644
Over time	5,999	1,245	4,068	130	350	11,792
Revenues	**275,529**	**21,265**	**97,866**	**14,268**	**4,508**	**413,436**
Total Assets (restated)*	1,237,751	14,207	3,450	22,830	-	1,278,238
Capital expenditure	46,966	118	-	41	-	47,125

- At the end of 2023, in line with the change of the accounting policy, the deferred tax related to investment tax benefits was recognised retrospectively as of 31 December 2022.

Revenues from external customers are derived from the sale of goods, revenue from services and royalty incomes as described below as of 30 June 2024 and 2023.

Analyses of revenue by category	**2024**	**2023**
	HUFm	HUFm
Sale of pharmaceutical products	302,874	317,580
Revenue from services	12,020	9,427
Royalty income	104,799	86,429
Total revenues	**419,693**	**413,436**

In the first half year of 2024, revenues of approximately HUF 102,019m (2023 half year: HUF 83,963m) are derived from a single external customer (AbbVie) that 24.31% of total revenues. The revenue is related to royalty payments of Vraylar® and are attributable to the Neuropsychiatry segment and located in the USA region. There was no other customer exceeding 10% of revenues in the first half year either in 2024 or in 2023.

4. Profit and loss information

	2024	**2023**
	6 months to June	**6 months to June**
	HUFm	HUFm
Other income	**9,535**	**5,370**
from this: Milestone revenue	2,679	597
Other expenses	**(22,659)**	**(26,399)**
from this: Impairment and scrapping of inventories	(7,648)	(2,045)
from this: Supplementary pharmaceutical tax	-	(12,462)
from this: Claw-back expenses	(5,703)	(5,552)
Reversal of impairment /(impairment) on financial and contract assets	**624**	**(96)**
Other operating results	**(12,500)**	**(21,125)**

In the reported period the Group received HUF 2,679m one-off payments while in the reference period it was HUF 597m (Biotechnology unit).

The rules of the supplementary pharmaceutical tax, introduced on 23 December 2022 and previously recognised as Other expenses (HUF 12,462m in the first half of 2023), were amended on 25 January 2024. Based on legislative changes effective from 2024, this tax can be reduced to zero by the amount of the newly introduced extraordinary tax in 2024, which according to our accounting policies is recognised as an income-type tax and is eligible to be counted in the amount of the Global Minimum Tax payable.

Claw-back expenses are partial repayments of the received Sales revenue of the reimbursed products to the State where the product was distributed (further "claw-back"). In accordance with the announced claw-back regime local authorities established the amount of extraordinary tax to be paid based on the comparison of the subsidies allocated for reimbursed drugs and manufacturers' sales thereof. Other expenses include expenditures in respect of the claw-back regimes effective in Hungary, Romania, Germany, France, Spain, Portugal, Belgium, Italy, Bulgaria, Austria, Poland, Latvia, Lithuania, Croatia, Slovenia, Greece, Ireland, UK and Switzerland amounting to HUF 5,703m in the first half of 2024 (in 2023 half year: HUF 5,552m).

5. Net financial result

The Group is translating its foreign currency monetary assets and liabilities to the period-end exchange rate on individual item level, which is presented in the Consolidated Income Statement separately as “Finance income” or “Finance costs”. Since the Management of the Group is analysing these translation differences on net basis, balances are presented on net basis as follows:

	2024 6 months to June HUFm	**2023 6 months to June** HUFm
Unrealised financial items	**21,196**	**(24,074)**
Exchange gain/(loss) on trade receivables and trade payables	18,345	(16,897)
Gain/(Loss) on foreign currency loans receivable	1,027	(7,592)
Gain/(Loss) on foreign currency securities	929	(1,782)
Result of unrealised forward exchange contracts	(365)	2,122
Unrealised profit of cash-flow hedge (reclassification from OCI)	188	-
Foreign exchange difference of other financial assets and liabilities	(91)	(268)
Unwinding of discounted value related to contingent-deferred purchase price liabilities	(40)	(39)
Interest expenses related to IFRS 16 standard	(510)	(379)
Foreign exchange difference related to IFRS 16 standard	(108)	147
Unrealised fair value difference on financial instruments	1,829	833
Impairment of securities	(8)	(219)
Realised financial items	**3,046**	**(787)**
Gain on forward exchange contracts	16	4,201
Exchange gain/(loss) realised on trade receivables and trade payables	687	(19,301)
Foreign exchange difference on conversion of cash	517	(2,668)
Dividend income	7	5
Interest income	10,101	13,046
Interest expense	(7,576)	(8,623)
Realised (loss)/gain on derivatives	(135)	2,347
Result of sale and derecognition of debt and equity instruments	(237)	(1,952)
Disposal of subsidiaries	-	12,000
Other financial items	(334)	158
Total	**24,242**	**(24,861)**

The unrealised fair value difference on financial instruments was HUF 1,829m loss in the first half year period of 2024, which consist of HUF 1,822m loss for government securities and corporate bonds, HUF 3,184m gain for debt on issue of bond, HUF 467m gain for derivatives. In the first half of 2023 this fair value difference was HUF 833m gain.

From 2021, the Company enters into cash-flow hedging transactions. In the first half of 2024, it realized financial loss of HUF 135m (in first half of 2023 gain of HUF 2,347m).

In addition to this, the Company also concludes futures transactions for trading purposes. In the first half of 2023, on these transactions the Company realized HUF 16m financial gain. The reason for this was primarily the change in the USD and EUR exchange rate. In the first half of 2023, on these transactions the Company realized HUF 4,201m financial gain.

During the current half year, some of the US Treasury Bills were sold from the debt instruments valued at AC. Financial loss of HUF 237m was generated from the exchange rate difference realized at the disposal. In the first half of 2023, on the sold of debt instruments (government bonds) were realized loss of HUF 1,952m.

6. Income tax

	2024 6 months to June HUFm	2023 6 months to June HUFm
Corporate income tax	(8,769)	(2,365)
Local business tax	(3,489)	(3,217)
Innovation contribution	(525)	(485)
GLOBE tax	(7,472)	-
Current tax	**(20,255)**	**(6,067)**
Deferred tax	2,433	2,258
Deferred tax	**2,433**	**2,258**
Income tax	**(17,822)**	**(3,809)**

In the first half 2024 the average effective tax rate calculated on the basis of the current tax is 12.9% and also 11.4% taking into account the effect of deferred tax as well, in 2023 these rates were 8.3% and 5.2% respectively.

Due to the derecognition of the right of use intangible assets as part of the settlement of the pre-exsisting relationship related to the new acquisitions (Note 17) deferred tax assets and deferred tax income have been recognised in the amount of HUF 3,709m.

7. Consolidated earnings per share

As of 30 June 2024 and 30 June 2023 there are no potential dilutive instruments issued by the Group, that would modify the basic EPS.

EPS (basic and diluted)

	2024 6 months to June	2023 6 months to June
Net consolidated profit attributable to owners of the parent (HUFm)	138,215	67,936
Weighted average number of ordinary shares outstanding (thousands)	182,843	185,880
Earnings per share (HUF)	**756**	**365**

8. Financial instruments

This note provides an update on the judgements and estimates made by the Group in determining the fair values of the financial instruments since the last annual financial report.

The Group holds the following financial assets and liabilities. It does not include fair value information for financial assets and liabilities measured at amortised cost if the carrying amount is a reasonable approximation of fair value.

The risk management policy for financial instruments are presented unter Note 7 of the Management Report.

	Carrying value		Fair value	
	2024	2023	2024	2023
	30 June	31 December	30 June	31 December
	HUFm	HUFm	HUFm	HUFm
Financial assets measured at fair value[1]				
Financial assets measured at FVOCI				
Government securities, corporate bonds (debts)[2]	19,522	28,346	19,522	28,346
Equity instruments	6,799	36,326	6,799	36,326
Investments	41,786	8,521	41,786	8,521
	68,107	**73,193**	**68,107**	**73,193**
Financial assets measured at FVTPL				
Government securities, corporate bonds[2] – designated as at FVTPL at initial recognition	74,556	75,839	74,556	75,839
Other financial asset (Mycovia)	0	0	0	0
Derivative financial instruments	17,492	15,075	17,492	15,075
Foreign currency forwards and commodity swaps cash flow hedges	1,711	10,914	1,711	10,914
	93,759	**101,828**	**93,759**	**101,828**
Financial assets measured at amortised cost[1]				
Government securities, corporate bonds (debts)	854	6,140	761	40,205
Loan receivables[3]	1,270	4,219	1,270	4,219
Trade receivables	234,136	204,968	234,136	204,968
Cash and cash equivalents	56,920	80,493	56,920	80,493
	293,180	**295,820**	**293,087**	**329,885**

(1) All financial assets are free from liens and charges.
(2) The fair value of interest rate swap was discounted to present value by the Group using the available interest rate curve on the market. In case of those corporate bonds, which are recognised under the fair value option, the present value was determined using the discounted cash-flow method. Based on the mentioned valuation techniques the financial instruments were assigned to Level 2 and Level 3 category.
(3) There is not significant different between the carrying value and fair value of the loan receivables.

	Carrying value		Fair value	
	2024	2023	2024	2023
	30 June	31 December	30 June	31 December
	HUFm	HUFm	HUFm	HUFm
Financial liabilities measured at fair value				
Financial liabilities measured at FVTPL				
Debt on the issue of bonds	51,023	53,840	51,023	53,840
Derivative financial instruments	13,716	11,401	13,716	11,401
Foreign currency forwards and commodity swaps – cash flow hedges	2,141	947	2,141	947
Other financial liabilities	9,758	3,349	9,758	3,349
	76,638	**69,537**	**76,638**	**69,537**
Financial liabilities measured at amortised cost				
Borrowings	35,981	182	35,981	182
Trade payables	45,316	51,301	45,316	51,301
Lease liabilities	19,763	18,245	19,763	18,245
	101,060	**69,728**	**101,060**	**69,728**

Above mentioned different levels have been defined as follows:
Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities (government bonds, corporate bonds, ETFs).
Level 2: Inputs other than quoted prices included within Level 1 that are observable at the market for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices– foreign currency forwards, commodity swaps, debt instruments which calculated with DCF method)).
Level 3: Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs– venture capital and other financial investments, debt instruments for which no quoted market price is available).

8.1 Fair value hierarchy

The levels in the fair value hierarchy into which the recurring fair value measurements are categorised are as follows:

	30 June 2024				31 December 2023			
	Level 1	**Level 2**	**Level 3**	**Total**	**Level 1**	**Level 2**	**Level 3**	**Total**
	HUFm	HUFm	HUFm	HUFm	HUFm	HUFm	HUFm	HUFm
Financial assets								
Non-current financial assets at FVTPL	**66,482**	**8,074**	**-**	**74,556**	**67,585**	**8,254**	**-**	**75,839**
Debt instruments	66,482	8,074	-	74,556	67,585	8,254	-	75,839
Financial assets at FVOCI	**66,334**	**-**	**1,773**	**68,107**	**71,502**	**-**	**1,691**	**73,193**
Debt instruments	18,673	-	849	19,522	27,521	-	825	28,346
Equity instruments	47,661	-	924	48,585	43,981	-	866	44,847
Derivative financial instruments	**-**	**19,203**	**-**	**19,203**	**-**	**25,989**	**-**	**25,989**
Interest rate and commodity swaps	-	17,492		17,492	-	15,054	-	15,054
Foreign currency forwards – trading derivatives	-	-	-	-	-	21	-	21
Foreign currency forwards and commodity swaps – cash-flow hedges	-	1,711	-	1,711	-	10,914	-	10,914
Total	**132,816**	**27,277**	**1,773**	**161,866**	**139,087**	**34,243**	**1,691**	**175,021**

	30 June 2024				31 December 2023			
	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
	HUFm	HUFm	HUFm	HUFm	HUFm	HUFm	HUFm	HUFm
Financial liabilities								
Financial liabilities at FVTPL	**-**	**58,851**	**-**	**58,851**	**-**	**54,864**	**-**	**54,864**
Debt on issue of bonds	-	51,023	-	51,023	-	53,840	-	53,840
Other financial liabilities at fair value	-	7,828	-	7,828	-	1,024	-	1,024
Derivative financial instruments	**-**	**15,857**	**-**	**15,857**	**-**	**12,348**	**-**	**12,348**
Interest rate and commodity swaps	-	13,325	-	13,325	-	11,354		11,354
Foreign currency forwards – trading derivatives	-	391	-	391	-	47		47
Foreign currency forwards and commodity swaps – cash-flow hedges	-	2,141		2,141	-	947	-	947
Total	**-**	**74,708**	**-**	**74,708**	**-**	**67,212**	**-**	**67,212**

9. Derivative financial instruments

Government bonds and corporate bonds purchased by the Parent Company are fixed interest rate debt securities. In order to manage the market risk arising from fixed interest rates, the Parent has entered into interest rate swaps in the case of debt instruments, during which it exchanges fixed interest rates for variables. The maturity and currency data of these transactions are summarized in the table below.

Assets

Name	Nominal value	Maturity date	Carrying value (HUFm)
Interest rate swap (HUF)	7,000,000,000	2028	924
Interest rate swap (HUF)	10,000,000,000	2029	2,003
Interest rate swap (HUF)	3,500,000,000	2030	676
Interest rate swap (HUF)	49,000,000,000	2031	10,391
Interest rate swap (EUR)	2,000,000	2026	38
Interest rate swap (EUR)	10,000,000	2027	438
Interest rate swap (EUR)	13,775,000	2029	807
Interest rate swap (EUR)	25,000,000	2035	2,182
Total	-	-	**17,459**

Liabilities

Name	Nominal value	Maturity date	Carrying value (HUFm)
Interest rate swap (HUF)	7,000,000,000	2028	(924)
Interest rate swap (HUF)	10,000,000,000	2029	(1,620)
Interest rate swap (HUF)	3,500,000,000	2030	(676)
Interest rate swap (HUF)	49,000,000,000	2031	(10,105)
Total	-	-	**(13,325)**

The Group's derivative instruments are interest rate-, commodity swaps (certain parts of them – TTF swap short positions to manage hedging inefficiency) and foreign currency forwards.

Derivatives are only used for economic hedging purposes and not as speculative investments. However, where derivatives do not meet the hedge accounting criteria, they are classified as "held for trading" for accounting purposes and are accounted for at fair value through profit or loss.

In 2021 the Group recognized the corporate bonds and related interest rate swaps at fair value through profit or loss due to eliminate or materially reduce recognition or measurement inconsistencies (accounting mismatch) which would have existed, if the Group had not selected the fair value option based on IFRS 9. The fair value option was selected at initial measurement and recognition.

	30 June 2024	31 December 2023
	HUFm	HUFm
Assets		
Long-term derivative financial instruments		
Interest rate swaps	17,459	14,935
Foreign currency forwards – trading derivatives	-	-
Foreign currency forwards and commodity swaps – cash flow hedges	16	1,392
Short-term derivative financial instruments		
Interest rate and commodity swaps	33	119
Foreign currency forwards – trading derivatives	-	21
Foreign currency forwards and commodity swaps – cash flow hedges	1,695	9,522
Total derivative financial assets	**19,203**	**25,989**
Liabilities		
Long-term derivative financial instruments		
Interest rate swaps	(13,325)	(11,354)
Foreign currency forwards – trading derivatives	-	-
Foreign currency forwards and commodity swaps – cash flow hedges	(394)	(59)
Short-term derivative financial instruments		
Interest rate and commodity swaps	-	-
Foreign currency forwards – trading derivatives	(391)	(47)
Foreign currency forwards and commodity swaps – cash flow hedges	(1,747)	(888)
Total derivative financial liabilities	**(15,857)**	**(12,348)**

The transactions managed by the Company under cash-flow hedge accounting are described in detail in the following subsections:

Foreign currency forwards - USD Vraylar royalty revenues	**30 June 2024**	**31 December 2023**
Carrying amount of the hedging instrument - liabilities (HUFm)	(42)	10,914
Notional amount (USD)	363,750,000	338,950,000
Maturity date	2024/2025	2024/2025
Hedge ratio*	100%	100%
Change in the fair value of outstanding hedging instruments since inception of the hedge	(10,956)	12,618
Change in value of hedged item used to determine hedge ineffectiveness	-	-
Weighted average forward rate for outstanding hedging instruments (including forward points) USD/HUF	371.76	351.95

* The foreign currency forward is denominated in the same currency (USD) as the highly probable royalty income, therefore the hedge ratio is 1:1.

TTF SWAP commodity hedge	30 June 2024	31 December 2023
Carrying amount of the hedging instrument (HUFm)	(192)	(604)
Notional amount (MWh)	38,631	87,888
Maturity date	2024	2024
Hedge ratio*	100%	100%
Change in the fair value of outstanding hedging instruments since inception of the hedge (HUFm)	412	(604)
The ineffective portion of the change in the fair value of the hedging instrument (HUFm)	183	(271)
Weighted average forward rate for outstanding hedging instruments (including forward points) EUR/MWh	37.86	34.45

* The TTF commodity swap is denominated in the same TTF prices (TTF Argus month-ahead) as the highly probable natural gas expenses, therefore the hedge ratio is 1:1.

Foreign currency forward - Natural gas (EUR)	30 June 2024	31 December 2023
Carrying amount of the hedging instrument (HUFm)	(34)	(80)
Notional amount (EUR)	1,065,004	2,634,504
Maturity date	2024/2025	2024
Hedge ratio*	100%	100%
Change in the fair value of outstanding hedging instruments since inception of the hedge (HUFm)	46	(80)
The ineffective portion of the change in the fair value of the hedging instrument (HUFm)	1	(6)
Weighted average forward rate for outstanding hedging instruments (including forward points) EUR/HUF	399.43	389.69

* The foreign currency forward is denominated in the same currency (EUR) as the highly probable natural gas expenses, therefore the hedge ratio is 1:1.

Foreign currency forward - Electricity (EUR)	30 June 2024	31 December 2023
Carrying amount of the hedging instrument (HUFm)	(162)	(263)
Notional amount (EUR)	6,568,901	9,986,912
Maturity date	2024/2025	2024
Hedge ratio*	100%	100%
Change in the fair value of outstanding hedging instruments since inception of the hedge (HUFm)	101	(263)
The ineffective portion of the change in the fair value of the hedging instrument (HUFm)	-	-
Weighted average forward rate for outstanding hedging instruments (including forward points) EUR/HUF	398.80	392.04

* The foreign currency forward is denominated in the same currency (EUR) as the highly probable electricity expenses, therefore the hedge ratio is 1:1.

10. Property, plant and equipment

	30 June 2024 HUFm	31 December 2023 HUFm
Property, plant and equipment without Right-of-use assets	340,727	329,617
Right-of-use assets	19,194	17,777
Total	**359,921**	**347,394**

10.1 Property, plant and equipment without Right-of-use assets

	Land and buildings HUFm	Plant and equipment HUFm	Construction in progress HUFm	Total HUFm
Gross value				
at 31 December 2022	**221,430**	**368,423**	**58,865**	**648,718**
Translation differences	(5,292)	(5,445)	(922)	**(11,659)**
Effect of newly acquired companies	-	51	-	**51**
Additions	17,792	27,556	(45,348)	**-**
Transfers and capital expenditure	3,808	1,649	61,979	**67,436**
Disposals	(2,700)	(7,228)	(197)	**(10,125)**
Disposal of subsidiary	(859)	(2,876)	(5)	**(3,740)**
at 31 December 2023	**234,179**	**382,130**	**74,372**	**690,681**
Accumulated depreciation				
at 31 December 2022	**76,043**	**271,197**	**-**	**347,240**
Translation differences	(894)	(3,737)	-	**(4,631)**
Effect of newly acquired companies	-	26	-	**26**
Current year depreciation	6,493	19,608	-	**26,101**
Net foreign currency exchange differences	(13)	(42)	-	**(55)**
Disposals	1,083	(6,230)	-	**(5,147)**
Disposal of subsidiary	(446)	(2,024)	-	**(2,470)**
at 31 December 2023	**82,266**	**278,798**	**0**	**361,064**
Net book value				
at 31 December 2022	**145,387**	**97,226**	**58,865**	**301,478**
at 31 December 2023	**151,913**	**103,332**	**74,372**	**329,617**

	Land and buildings HUFm	Plant and equipment HUFm	Construction in progress HUFm	Total HUFm
Gross value				
at 31 December 2023	**234,179**	**382,130**	**74,372**	**690,681**
Translation differences	2,660	3,477	985	**7,122**
Effect of newly acquired companies (see Note 17)	-	358	-	**358**
Additions	3,527	9,844	(13,372)	**(1)**
Transfers and capital expenditure	1,654	735	19,748	**22,137**
Disposals	(2,047)	(7,390)	(50)	**(9,487)**
Disposal of subsidiary	-	-	-	**-**
at 30 June 2024	**239,973**	**389,154**	**81,683**	**710,810**
Accumulated depreciation				
at 31 December 2023	**82,266**	**278,798**	**-**	**361,064**
Translation differences	717	2,430	-	**3,147**
Effect of newly acquired companies (see Note 17)	-	177	-	**177**
Current year depreciation	2,865	9,226	-	**12,091**
Net foreign currency exchange differences	15	61	-	**76**
Disposals	(115)	(6,357)	-	**(6,472)**
Disposal of subsidiary	-	-	-	**-**
at 30 June 2024	**85,748**	**284,335**	**0**	**370,083**
Net book value				
at 31 December 2023	**151,913**	**103,332**	**74,372**	**329,617**
at 30 June 2024	**154,225**	**104,819**	**81,683**	**340,727**

All items of Property, plant and equipment are free from liens and charges. The amount of Land and buildings does not contain any Investment property.

10.2 Right-of-use assets

	Building HUFm	Land HUFm	Machinery HUFm	Office equipment HUFm	Vehicles HUFm	Total HUFm
Net book value as at 1 January 2023	**7,969**	**1,628**	**1**	**117**	**4,756**	**14,471**
Additions/(Disposals)	4,740	369	5	(76)	3,509	8,547
Current year depreciation	(2,672)	(27)	(3)	(15)	(2,524)	(5,241)
Net book value as at 31 December 2023	**10,037**	**1,970**	**3**	**26**	**5,741**	**17,777**
Additions/(Disposals)	1,938	17	1	4	2,184	4,144
Current year depreciation	(1,244)	(15)	(1)	(7)	(1,460)	(2,727)
Net book value as at 30 June 2024	**10,731**	**1,972**	**3**	**23**	**6,465**	**19,194**

11. Goodwill

Goodwill arising on acquisitions are recorded in the functional currency of the acquired entity and translated at period end closing rate.

	Goodwill
	HUFm
Cost	
At 1 January 2023	**35,101**
Exchange differences	(3,198)
at 31 December 2023	**31,903**
At 1 January 2024	31,903
Increase deriving from acquisition*	40,074
Exchange differences	1,976
at 30 June 2024	**73,953**

* The measurement period is not closed yet for the acquisition of the companies purchase price allocation as the management is still seeking for more information to finalise the calculation, which could affect the goodwill. See details in Note 17.

12. Other intangible assets

	30 June 2024	**31 December 2023**
	HUFm	HUFm
Other intangible assets	142,465	180,656
Intangibles generated internally	119,049	49,727
Total	**261,514**	**230,383**

12.1 Other intangible assets

	Rights	Intellectual property	Research and development	Total other intangible assets
	HUFm	HUFm	HUFm	HUFm
Gross value				
at 31 December 2022	**312,637**	**6,826**	**423**	**319,886**
Translation differences	(128)	(55)	-	**(183)**
Increase deriving from acquisition	14,142	-	-	**14,142**
Increase	41,324	1,135	-	**42,459**
Disposals	(6,846)	395	-	**(6,451)**
Disposal of subsidiary	(3,570)	(558)	-	**(4,128)**
at 31 December 2023	**357,559**	**7,743**	**423**	**365,725**
Accumulated depreciation				
at 31 December 2022	**159,649**	**5,233**	**423**	**165,305**
Translation differences	105	(48)	-	**57**
Current year amortisation	15,947	376	-	**16,323**
Net foreign currency exchange differences	3	2	-	**5**
Impairment and reversal of impairment (net)	4,127	-	-	**4,127**
Disposals	(252)	303	-	**51**
Disposal of subsidiary	(441)	(358)	-	**(799)**
at 31 December 2023	**179,138**	**5,508**	**423**	**185,069**
Net book value				
at 31 December 2022	**152,988**	**1,593**	**-**	**154,581**
at 31 December 2023	**178,421**	**2,235**	**-**	**180,656**

	Rights	Intellectual property	Research and development	Total other intangible assets
	HUFm	HUFm	HUFm	HUFm
Gross value				
at 31 December 2023	**357,559**	**7,743**	**423**	**365,725**
Translation differences	499	135	-	**634**
Additions	15,728	170	2,564	**18,462**
Disposals*	(108,429)	(10)	-	**(108,439)**
at 30 June 2024	**265,357**	**8,038**	**2,987**	**276,382**
Accumulated depreciation				
at 31 December 2023	**179,138**	**5,508**	**423**	**185,069**
Translation differences	98	73	-	**171**
Current year amortisation	6,071	251	-	**6,322**
Net foreign currency exchange differences	2	3	-	**5**
Disposals*	(57,650)	-	-	**(57,650)**
at 30 June 2024	**127,659**	**5,835**	**423**	**133,917**
Net book value				
at 31 December 2023	**178,421**	**2,235**	**-**	**180,656**
at 30 June 2024	**137,698**	**2,203**	**2,564**	**142,465**

* It includes the derecognition of pre-exsisiting relationship (Note 17).

All intangible assets are free from liens and charges. The intangible assets of the Group, except for R&D, are not own produced.

12.2 Intangibles generated internally

TERIPARATIDE

As of 31 May 2024, the Company acquired the remaining 50% of the shares in Richter-Helm BioTec GmbH&Co KG (HBTC) from the non-controlling external owner (HELM AG). The transaction qualifies as an asset deal, the cost of acquisition was generally allocated to a new intangible asset at the value of HUF 33,764m (Note 17). The estimated useful life for the rights is 10 years. The amortization period started in June 2024. Net book value of the rights is HUF 33,970m as of 30 June 2024.

13. Investments in associates and joint ventures

	2024 30 June HUFm	2023 31 December HUFm
At 1 January	**15,177**	**9,281**
Acquisition/capital increase	-	2,654
Share of profit of associates and joint ventures	5,902	6,134
Net investments	(4,335)	(416)
Dividend	(58)	(938)
Reclassification to subsidiary *	(2)	-
Impairment	-	(1,624)
Exchange difference	(59)	86
At the end of 30 June / 31 December	**16,625**	**15,177**
out of investment in associates	15,308	13,853
out of investment in joint ventures	1,317	1,324

* See the effect of acquisition of Richter-Helm BioTec GmbH&Co KG. in Note 17.

14. Non-controlling interest

The total non-controlling interest as of 30 June 2024 is HUF 3,606m (in 31 December 2023 HUF 11,767m).

As of 31 May 2024, the Company acquired the remaining 30% of the shares in Richter-Helm BioLogics GmbH & Co. KG (HBLC) and Richter-Helm BioLogics Management GmbH (HBLM) from the non-controlling external owner (HELM AG). See the effect of the acquisition in Note 17.

15. Provisions

	30 June 2024 HUFm	31 December 2023 HUFm
Short-term provisions	1,508	2,961
Long-term provisions	6,418	6,559
from this defined retirement benefit plans	*6,269*	*5,602*
Total	**7,926**	**9,520**

16. Dividend on ordinary shares

Dividends approved in the first half of 2024 and 2023:

	2024 HUFm	2023 HUFm
Dividend on ordinary shares	78,837	72,686

A dividend of HUF 423 per share (HUF 78,8bn) was declared in respect of the 2023 results.

17. Business combination

Richter-Helm BioTec GmbH&Co KG.

As of 31 May 2024, the Company acquired the remaining 50% of the shares in Richter-Helm BioTec GmbH&Co KG (HBTC) from the non-controlling external owner (HELM AG).

The transaction had been identified as asset acquisition, based on an asset concentration test.

Total consideration transfered in cash was EUR 85.64m and EUR 13.8m contingent consideration had been stated in the agreement.

Acquisition-related costs of HUF 58.6m were directly attributed to the acquisition of the shares.

	31 May 2024 HUFm
Consideration transfered	**33,391**
Investments	4
Trade receivables	1,796
Other current assets	1,306
Cash and cash equivalents	3,904
Trade payables	(52)
Other current liabilities and accruals	(542)
Net asset acquired	**6,416**
Settlement of pre-existing relationship	(2,038)
Previously held equity interest	(4,751)
Cost of the identified asset acquired in the asset acquisition	**33,764**

The pre-existing relationship between the parties has been settled at the date of the acquisition. As part of this settlement the right of use intangible assets which were already recognized in the consolidated books based on the licence agreements agreed prior to the acquisition were derecognised. The cost of those right of use assets were also included as part of the cost of the acquisition.

The previously held equity interest in HBTC held by Gedeon Richter immediately before the acquisition date is not remeasured to its fair value based on our accounting policy choice according to the cost-based approach for an asset acquisition.

HBTC was consolidated as a jointly controlled entity until 31 May 2024, so its whole year profit has been presented in the Condensed Consolidated Income Statement.

Richter-Helm BioLogics GmbH & Co. KG

As of 31 May 2024, the Company acquired the remaining 30% of the shares in Richter-Helm BioLogics GmbH & Co. KG (HBLC).

Total consideration transfered in cash was EUR 40.6m. No contingent consideration had been stated in the agreement.

Acquisition-related costs of HUF 58.6m that were not directly attributable to the acquisition of the shares are included in administrative expenses in the Statement of profit or loss and in operating cash-flows in the Consolidated Cash-Flow Statement.

Estetra SRL and Neuralis SA

As of 11 June 2024, Gedeon Richter acquired 100% of the shares in Estetra SRL („Estetra") and Neuralis SA („Neuralis") from Mithra Pharmaceuticals SA. The purchase price was EUR 93.9m out of which EUR 41.9m was transferred to an escrow account. Neither deferred payment, nor contingent consideration was recognised as part of this transaction. Given that a purchase consideration of EUR 93.9m (equity value) had been agreed upon for the acquisition of the assets that constitute the E4 platform, the acquired entities were treated as one CGU as the acquired assets are expected to be integrated into Gedeon Richter's existing operations.

The key acquired assets are the own-developed lead platform, based on Estetrol (E4), a unique, native estrogen, a key asset to Richter's WHC's Business Unit. The transfer includes the related intellectual property rights, current contracts as well as the commitments related to Estelle (already marketed) and Donesta (in development, ahead of filing for marketing authorization).

The pre-existing relationship between the parties has been settled at the date of the acquisition (in amount of EUR 100.9m), separately from the business combination. As part of this settlement the right of use intangible assets which were already recognized in the Consolidated Financial Statements based on the licence agreements agreed prior to the acquisition were derecognised. The difference between the carrying value and the fair value of the right of use assets derecognised are recognised in the profit or loss in the value of EUR 3.2m.

The measurement period is not closed yet for the acquisition of the companies purchase price allocation as the management is still seeking for more information to finalise the calculation, which could affect the preliminary figures: net asset, deferred tax liability and the goodwill.

The preliminary values of the assets and liabilities recognised as a result of the acquisition are as follows:

	Carrying value	**Fair value**
	HUFm	HUFm
Total consideration	**36,588**	**36,588**
Property, plant and equipment	177	177
Other intangible assets	9,043	41,411
Other non-current receivables	2,818	2,818
Inventories	10,915	10,915
Trade receivables	1,725	1,725
Other current assets	9,359	9,359
Cash and cash equivalents	466	466
Borrowings (long- and short term)	(21,631)	(21,631)
Trade payables	(2,860)	(2,860)
Deferred tax liability	-	(6,211)
Net asset acquired	**10,012**	**36,169**
Derecognised pre-existing relationship	(39,182)	(37,954)
Goodwill	**-**	**38,373**

As part of the preliminary purchase price allocation analysis, Estella, Donesta and the E4 Development Programme had been identified and recognized as intangible assets in the total value of EUR 106.6m (Estelle EUR 59m, Donesta EUR 41m,

E4 EUR 6.6m). The valuation method used to determine the fair value of Estelle and Donesta is the Multi-Period Excess earnings Method. The E4 Development Programme has been valued using a cost based approach, based on inflation-adjusted costs.
Factors that make up the goodwill recognised include expected synergies from the combining operations and potential future prospects. It will not be deductible for tax purposes.

The amounts of revenue and profit or loss of Estetra and Neuralis since the acquisition date included in the consolidated statement of comprehensive income for the reporting period is not material on consolidated level.

The amount of acquisition-related costs recognised as an expense is HUF 240m, which mainly relate to legal fees .

Disclosing revenue and profit information for the combined entities for the first half of 2024 is impracticable, since such data is not readily available and the costs of obtaining that information would exceed its utility to readers.

BCI Pharma

As of 19 June 2024, Gedeon Richter acquired 100% of the shares in BCI Pharma („BCI Belgium”), a limited liability company incorporated under the laws of Belgium, and in its 100% owned subsidiary BCI Pharma („BCI France”), a simplified joint stock company incorporated under the laws of France. The total purchase price was EUR 8.4m out of EUR 5.2m was paid at the date of acquisition and EUR 3.2m is the net present value of the contingent consideration.

BCI Pharma is an R&D company which provides a drug discovery platform and proprietary screening technology for rapid identification & optimization of highly potent and selective kinase inhibitors.

The measurement period is not closed yet for the acquisition of the companies purchase price allocation as the management is still seeking for more information to finalise the calculation, which could affect the preliminary figures: net asset, deferred tax liability and the goodwill.

The preliminary values of the assets and liabilities recognised as a result of the acquisition are as follows:

	Carrying value HUFm	**Fair value** HUFm
Total consideration	**3,375**	**3,375**
Property, plant and equipment	4	4
Other intangible assets	135	2,349
Other non-current receivables	117	117
Trade receivables	85	85
Other current assets	28	28
Cash and cash equivalents	34	34
Borrowings (long- and short term)	(177)	(177)
Trade payables	(120)	(120)
Other current liabilities and accruals	(19)	(19)
Provisions	(40)	(40)
Deferred tax liability		(587)
Net asset acquired	**47**	**1,674**
Goodwill	**-**	**1,701**

As part of the preliminary purchase price allocation analysis, according to IFRS 3 an in-progress research and development (“IP R&D”) asset was identified in the value of EUR 5.9m which had been valued using a cost approach, based on inflation-adjusted costs.

Factors that make up the goodwill recognised include expected synergies from the combining operations and potential future prospects. It will not be deductible for tax purposes.

The amounts of revenue and profit or loss of BCI Belgium and BCI France since the acquisition date included in the consolidated statement of comprehensive income for the reporting period is not material on consolidated level.

The amount of acquisition-related costs recognised as an expense is HUF 102m, which mainly relate to legal advice.

Disclosing revenue and profit information for the combined entities for the first half of 2024 is impracticable, since such data is not readily available and the costs of obtaining that information would exceed its utility to readers.

18. Contingent consideration

As part of the acquisition of BCI Pharma, a contingent consideration was recorded at net present value in the amount of EUR 3.2m. It is presented as Non-current financial liability at FVTPL in the Consolidated Balance Sheet The consideration will only be paid upon successful future completion of relevant milestones (phase studies) (please see Note 17).

19. Borrowings

	30 June 2024 HUFm	31 December 2023 HUFm
Borrowings short-term	357	182
Borrowings long-term	35,624	-
Total	**35,981**	**182**

The Group has long-term borrowings, arbitrage and short-term financing transactions.

The cash-flow impact of short-term security repurchase agreements with liquidity purposes was HUF 140 billion borrowing and HUF 105 billion repayment. In connection with this HUF 35 billion borrowings was presented in Condensed Consolidated Balance Sheet.

20. Notable events after period closing

On 18 July 2024 Richter announced that the European Medicines Agency (EMA) has accepted Richter’s two marketing authorization applications (MAAs) for its proposed biosimilar to denosumab.

III. Disclosures and Disclaimers

I, the undersigned declare, that Gedeon Richter Plc. takes full responsibility, that the interim management report published today, which contains the Group's 6 months to June 2024 results is prepared in accordance with the applicable accounting standards and according to the best of our knowledge. The report above provides a true and fair view of the financial position of Gedeon Richter Plc. and its subsidiaries included in the consolidation, it presents the major risks and factors of uncertainty, and it also contains an explanation of material events and transactions that have taken place during the reported period and their impact on the financial position of Gedeon Richter Plc. and its subsidiaries included in the consolidation.

Budapest, 6 August 2024

Gábor Orbán

Chief Executive Officer

This report and associated presentations and discussion contain forward-looking statements. These statements are naturally subject to uncertainty and changes in circumstances. Those forward-looking statements may include, but are not limited to, those regarding capital employed, capital expenditure, cash flows, costs, savings, debt, demand, depreciation, disposals, dividends, earnings, efficiency, gearing, growth, improvements, investments, margins, performance, prices, production, productivity, profits, reserves, returns, sales, share buy backs, special and exceptional items, strategy, synergies, tax rates, trends, value, volumes, and the effects of Richter merger and acquisition activities. These forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, but are not limited to developments in government regulations, foreign exchange rates, political stability, economic growth and the completion of on-going transactions. Many of these factors are beyond the company's ability to control or predict. Given these and other uncertainties, you are cautioned not to place undue reliance on any of the forward-looking statements contained herein or otherwise. The company does not undertake any obligation to release publicly any revisions to these forward-looking statements (which speak only as of the date hereof) to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as maybe required under applicable securities laws. Statements and data contained in this presentation and the associated slides and discussions, which relate to the performance of Richter in this and future years, represent plans, targets or projections.

The financial statements in this report cover the activities of Gedeon Richter Group and Gedeon Richter Plc. EUR and USD amounts have been converted from HUF at average exchange rates for indicative purposes only. Financial statements for six months period ended 30 June 2024 and 2023 are unaudited. Financial statements for the twelve months period ended 31 December 2023 are audited.

Appendix

Transactions with the subsidiaries in the six months to June 2024

Gedeon Richter Plc. in order to comply with the regulations of the Act LXVII of 2019 on the encouragement of long-term shareholder engagement and modification of certain acts with the purpose of legal harmonization (hereinafter: Act), based upon Subsection (5) 25 of the Act, hereby discloses such product supply and product- and service purchase transactions the Company entered into with its subsidiaries - defined in point b) Section 24 of the Act - in 6 months to June 2024, which falls under the scope of the referred Act because of their aggregated amount:

PRODUCT SUPPLY TRANSACTIONS		
Name of the related party	**Date of the transaction**	**Aggregated amount of the transaction HUFm**
GEDEON RICHTER PHARMA GmbH	6 Months to June 2024	7,004
GEDEON RICHTER IBÉRICA, S.A.	6 Months to June 2024	7,315
TOO "GEDEON RICHTER KZ"	6 Months to June 2024	7,936
GEDEON RICHTER - RUS JSC	6 Months to June 2024	56,501

PRODUCT- AND SERVICE PURCHASE TRANSACTIONS		
Name of the related party	**Date of the transaction**	**Aggregated amount of the transaction HUFm**
GEDEON RICHTER POLSKA SP.Z.O.O.	6 Months to June 2024	10,282
GEDEON RICHTER ROMANIA SA	6 Months to June 2024	10,465

Gedeon Richter Plc. does not have such open transaction the individual disclosure of which is set out by the Act.